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Abstract 
Perturbed regulation of programmed cell death (apoptosis) plays a major role in tumor 
development. The process of eliminating unwanted and damaged cells by apoptosis is 
based on complex molecule interactions. Studies of various diseases generally analyse 
patient samples in order to find markers or patterns in the data associated with the disease. 
However, for analysing biological processes like apoptosis, the focus of interest is to dis-
cover molecular mechanisms within cells and hence consider a different observational 
level. Simulation and analysis of differential equation models aid in elucidating complex 
interrelations on a mechanistic level. Nevertheless, interpretation of how molecules 
mechanisms give rise to a cellular process is complicated, time consuming and the bottle-
neck of systems biology research. 
In order to understand interactions and mechanisms of molecules involved in apoptosis on 
a systems level in the context of tumor development, this work combines analysis of pa-
tient data and analysis of molecular interactions. To achieve this aim, two different ap-
proaches were followed.  
The first approach analyses gene expression data of different tumor entities for their abil-
ity to undergo cell death in silico by simulation of a mathematical model of apoptosis. 
The second approach identifies hypothetical conditions required for apoptosis. To this 
end, a novel method for model analysis was developed to reveal multivariate control 
mechanisms of model behaviour. The method automatically suggests model components 
and their crucial interrelations for a specific system response 
Conditions concerning certain apoptotic molecules and molecule relations could be con-
firmed. Moreover, interactions and relations were found, which suggest new hypotheses 
how apoptosis as a system is governed by a few molecules in a specific way.  
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Zusammenfassung 
Die gestörte Regulation des programmierten Zelltods (Apoptose) spielt eine wichtige Rol-
le bei der Krebsentstehung. Der Prozess, der unerwünschte und beschädigte Zellen elimi-
niert, basiert auf komplexen Molekülinteraktionen. Studien zur Untersuchung von Er-
krankungen konzentrieren sich typischerweise auf die Analyse von Patientenproben, um 
auf diese Weise Marker oder Muster zu finden, die mit der Krankheit assoziiert werden 
können. Dagegen werden bei der Analyse biologischer Prozesse wie der Apoptose eine 
Ebene betrachtet, bei der Zellen und Moleküle im Mittelpunkt stehen mit dem Ziel mole-
kulare Mechanismen aufzudecken. Dabei unterstützen Simulation und Analyse von Diffe-
rentialgleichungsmodellen die Untersuchungen bei der Aufklärung der komplexen Zu-
sammenhänge. Jedoch ist die Interpretation inwiefern molekulare Mechanismen funktio-
nieren meist kompliziert und mit erheblichem Aufwand verbunden. Darüber hinaus stellt 
die Interpretation bezüglich molekularer Mechanismen einen Engpass in der systembio-
logischen Forschung dar.  
Um Interaktionen und Mechanismen der beteiligten Moleküle zu verstehen und in den 
Kontext zu Tumorentwicklung zu stellen, wurde in dieser Arbeit die Analyse von Patien-
tendaten und die Analyse molekularer Interaktionen verknüpft. 
Dabei wurden zwei verschiedene Ansätze verfolgt. Zum einen wurden Genexpressionsda-
ten verschiedener Tumorentitäten analysiert und auf ihre Apoptosefähigkeit durch ma-
thematische Simulation geprüft. Zum anderen wurden hypothetische Bedingungen unter 
denen Apoptose stattfinden kann durch Analyse mathematischer Modelle ermittelt. Zu 
diesem Zweck wurde eine neuartige Methode zur Modellanalyse entwickelt, die auf 
multivariate Kontrollmechanismen des Systemverhaltens hindeutet. Auf diese Weise 
werden nicht nur wichtige Komponenten des apoptotischen Systems sondern auch ihre 
mechanistische Beziehung in einem automatisierten Prozess vorgeschlagen. 
Die auf diese Weise gefundenen Bedingungen bezüglich bestimmter Moleküle und Rela-
tionen zueinander bestätigen bekannte Interaktionen, die für Apoptose wichtig sind. Des 
Weiteren wurden Interaktionen und Relationen gefunden, die neue Hypothesen vorschla-
gen, wie der programmierte Zelltod als System von wenigen Molekülen in bestimmter 
Weise kontrolliert wird. 
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1 Introduction 
Biological processes are characterized by the dynamic behaviour of interacting mole-
cules. These interactions are performed in an orchestrated fashion to perform a certain 
task or give rise to a specific cellular function. 
One important function is apoptosis, or programmed cell death. The activation of apop-
totic cell death is an essential mechanism of cells during the development and mainte-
nance of a healthy organism to eliminate infected or defective cells. Impaired function of 
cell death plays an important role in development of several diseases. The evasion from 
apoptosis is considered a hallmark of cancer [42] and assumed to arise from disruption of 
the apoptosis pathway. 
At the molecular level, several stimuli that trigger apoptosis have been identified. For the 
CD95/Fas-mediated apoptosis pathway, Bentele et al. revealed a threshold mechanism for 
cell death based on molecule levels and hence a cell’s fate to be dependent on relative 
molecule concentrations [11]. 
Concentrations of molecules can be measured at the gene expression level by DNA mi-
croarrays. Microarray technology has been widely used to analyse the molecular state of 
tissue samples with regard to its corresponding phenotype. This technology has led to the 
discovery of markers for various diseases, for prognosis or to assist in choosing the ap-
propriate therapy for a patient [34] [82]. 
In addition to finding individual genes that distinguish or characterize states or classes of 
samples, a globaltest [40] analyzes groups of genes towards their ability of distinguishing 
phenotypes and yields a significance measure for the association of the tested group with 
a phenotype or class. Tested sets can be pathways, i.e. groups of interacting proteins (or 
rather the genes that code for them) that act in a concerted manner to allow for flux of 
information or matter. High significance of the test suggests accumulation of changes 
within the tested pathway associated with the phenotype. 
 
1.1 Scope of thesis 
Signaling pathways of apoptosis are studied in this work based on the assumption that 
molecule concentrations are crucial for the decision whether to execute apoptosis. The 
dynamic behaviour of molecule interactions is simulated by mathematical models. These 
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models are constructed from ordinary differential equations (ODEs) and combined with 
microarray analysis of data sets from normal and tumor tissue in order to find mecha-
nisms at the molecular level that decide on cell fate in association with a certain disease 
phenotype. Hypotheses for mechanisms at the molecule level for a certain model and its 
system response are generated towards apoptosis as the cellular function of interest and 
connected to a phenotypic disease state resulting in dynamic or mechanistic features for 
phenotypes instead of single genes or groups of genes representing a static “snapshot” of 
the disease state. To this end, two main approaches were followed. 
 
1.2 Contribution and outline 
In this work the level of phenotypic observation in terms of a cancerous or non-cancerous 
disease state and the level of molecular cell signaling are jointly investigated by focussing 
on apoptosis as the biological process essential for phenotype development (Fig 1.1). 
 
 
Figure 1.1: Observational levels integrated in this thesis  
In order to understand interactions and mechanisms of molecules involved in apoptosis in the context of 
tumor development, the level of clinical phenotypes (left) is connected via the process apoptosis (middle) to 
molecular interactions on the pathway level (right). 
 
By connecting phenotypes to mechanistic models of a system of interacting molecules, 
the aim of this work is to answer how a phenotype, in this work a state of disease, relates 
to the molecular interaction dynamics that bring about a certain process, here apoptosis 
and in that way find a discriminative pattern similar to markers, but as dynamic or 
mechanistic features for cancer.  
To this aim gene expression analysis and mathematical modeling were combined. 
Phenotypes:
Cancer / Normal
Molecule Interactions:
Apoptosis Pathway
Process:
Apoptosis
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Two main approaches were followed to bridge disease state and inspection of molecular 
interaction mechanisms. 
The first approach questions if the molecular state measured by gene expression data can 
explain disruption of apoptosis in cancer by scaling input values of a mathematical model 
according to the observed gene expression levels of pathway components involved in 
apoptosis. This approach was performed in collaboration with Barbara Roider during a 
student project at the German Cancer Research Center. 
The second approach elucidates which conditions with respect to molecule abundances 
could theoretically lead to a certain cell fate according to the analysis of a mathematical 
model of apoptosis. These conditions can be tested by analyzing how frequently they are 
met in data from normal tissue compared to tumor tissue. 
For the second approach a novel method was developed. It detects relations of pathway 
component responsible for a defined systems (pathway) response in an automated fash-
ion. 
In chapter two of this thesis introduces apoptotic cell signaling by describing, pro- and 
anti-apoptotic molecules involved in apoptosis and how they are affected in different tu-
mor types. Contemporary experimental as well as computational methods from systems 
biology are explained in chapter three. Chapter four describes mathematical models of 
cell signaling pathways and experimental data sets analysed for this thesis. Chapter five 
presents how mathematical models and data are combined to bridge the mechanistic level 
of molecule interactions and the phenotype level in order to understand interactions and 
mechanisms of molecules in the context of tumor development. The results from these 
approaches are then given in chapter six. This thesis concludes with discussion and out-
look of the work in chapter seven. 
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2 Cell signaling and apoptosis 
Coordinated cell action is based on interactions of molecules, for the most part of pro-
teins, which constitute the cellular signaling system. Cell signaling enables communica-
tion between and within cells by signal perception, transmission and response of a cell to 
its environment. Signaling also plays a major role in cancer development. The six identi-
fied characteristics entitled as “The hallmarks of cancer”, self-sufficiency in growth sig-
nals, insensitivity to growth-inhibitory signals, limitless replicative potential, sustained 
angiogenesis, metastasis and evasion of programmed cell death (apoptosis) are largely 
based on cell signaling. This chapter comprises the basics about cell signaling during 
apoptosis and the importance of intact cell signaling to prevent carcinogenesis as well as 
examples for signaling pathway disruptions occurring in cancer development. 
 
2.1 Apoptosis - Cell death: An essential process for life 
Apoptosis is a type of cell death that has been described for the first time as a process 
involved in embryonic development by Carl Vogt in 1842. It is an essential process for 
tissue homeostasis, the development of organs and a multi-cellular organism [24] but has 
been also found to be implicated in a number of diseases, where either too much (e.g. in 
neurodegenerative diseases, Parkinson’s, Alzheimer’s, sinal muscular atrophy, AIDS) or 
too little apoptosis (e.g. in cancer or autoimmune diseases like diabetes type I and en-
cephalomyelitis) takes place [61]. 
While necrosis is described as an unordered and accidental form of cell death in response 
to acute injury which leads to uncontrolled disintegration of cellular structures, release of 
cytosolic content and subsequent inflammatory response, apoptosis occurs without leak-
age of cell content and thus without inflammation [61]. Instead, apoptosis is characterized 
by its induction in individual cells and their clean elimination. Morphological characteris-
tics of apoptosis are shrinkage and rounding of the cell, fragmentation of the nucleus, 
membrane blebbing and formation of membrane enclosed compartments called apoptotic 
bodies which are ingested by phagocytosis of non-apoptotic cells [50]. 
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Figure 2.1: Extrinsic and intrinsic apoptosis pathway 
For simplicity, the pro-apoptotic effect by Smac sequestering XIAP is not depicted in this figure. 
 
2.1.1 The extrinsic and the intrinsic apoptosis pathway 
On the molecular level, apoptosis is induced by cell signaling pathways. Two main path-
ways are common to mammalian cells: the extrinsic and the intrinsic apoptosis pathway. 
The extrinsic pathway is triggered by extra-cellular signals e.g. ligand binding to death 
receptors situated at the membrane of the target cell, while the intrinsic pathway is caused 
by cellular stress inducing mitochondrial outer membrane permeabilization (MOMP) fol-
lowed by release of apoptotic signaling proteins from the mitochondria into the cyto-
plasm. An overview of apoptotic pathways is illustrated in Fig. 2.1. 
Extrinsic apoptosis is mediated by ligand-induced activation of death receptors which are 
part of the tumor necrosis factor (TNF) receptor super-family including eight members: 
TNFR1 (DR1), CD95 (Fas/APO-1/DR2), DR3, TRAILR1 (APO-2/DR4), TRAILR2 
(DR5), DR6, EDAR and NGFR [59]. These death receptors are characterized by a pro-
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tein-protein interaction domain in their intracellular region called death domain (DD) [33] 
which couples the death receptors to the apoptosis-inducing machinery. 
Upon ligand activation, receptors recruit signaling molecules to their death domain. 
Among these molecules is FADD which, in addition to a DD also contains a death effec-
tor domain (DED). The DD of the receptor interacts with the DD of FADD whose DED 
enables interaction with molecules like initiator caspases or FLICE-like inhibitory pro-
teins (FLIPL/S/R/CFLAR) containing a DED [59]. The formation of a complex involving 
ligand, receptor and FADD able to bind procaspase-8/-10 and other proteins containing a 
DED is called death inducing signaling complex (DISC) [76] [51] and is found to be part 
of the CD95, TRAILR1 and TRAILR2 signaling pathway [77]. 
Binding of inactive initiator caspases (procaspase-8/-10) to the DISC leads to their activa-
tion and subsequent cleavage of more pro-death signaling molecules like effector cas-
pases to accomplish cell death [96]. 
Activation of the intrinsic apoptosis pathway is regulated by members of the Bcl-2 family 
and requires mitochondrial outer membrane permeabilization (MOMP) followed by the 
release of cytochrome-C and Smac/Diabolo from the mitochondrial inter-membrane 
space into the cytosol. Smac (second mitochondria-derived activator of caspases), Apaf-1 
(apoptotic-protease activating factor 1) and ATP/dATP then form the apoptosome, which, 
similarly to the DISC, acts as a complex to activate the initiator caspase-9 [10] able to 
cleave effector caspases. 
Smac further relieves XIAP-mediated inhibition active caspase-3 [86]. 
While the intrinsic pathway is reported to be triggered as a response to intracellular sig-
nals due to cellular stress like DNA damage, hypoxia or cytotoxic insults [25], the extrin-
sic pathway is responsible for T-cell selection and elimination of virus infected or trans-
formed cells [12]. 
The two pathways were shown to act independently [89], but also to be coupled through 
caspase-8 cleaving Bid, a pro-apoptotic Bcl-2 family member [97]. Both pathways con-
verge at caspase activation for execution of cell death. 
 
2.1.2 Caspases 
Both, the intrinsic and the extrinsic pathway lead to activation of caspases (cystein-
dependent aspartate specific proteases), which are considered as executioners of cell 
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death. Healthy cells contain several caspases as inactive precursors called caspase zymo-
gens or procaspases [57].  
The pro-apoptotic caspases can be divided into the group of initiator caspases involved in 
the initiation of the apoptotic response including procaspases-2, -8, -9 and –10, and the 
group of executioner caspases containing procaspases-3, -6, and –7 which cleave down-
stream many cellular substrates resulting in the characteristic features of cell death. 
The executioner caspases possess only short prodomains, whereas the initiator caspases 
have long prodomains containing death effector domains (DED) in the case of procas-
pases-8 and –10 or caspase recruitment domains (CARD) as in the case of procaspase-9 
and procaspase-2. Via their prodomains, the initiator caspases are recruited to and acti-
vated at death inducing signaling complexes either in response to the ligation of cell sur-
face death receptors (extrinsic apoptosis pathways) or in response to signals originating 
from inside the cell (intrinsic apoptosis pathway).  
The extrinsic apoptosis pathway includes recruitment of procaspase-8 by its DEDs to the 
death inducing signaling complex (DISC). Due to their close proximity to each other at 
the DISC, several procaspase-8 molecules become activated by autoproteolysis [28]. 
In contrast, procaspase-9 is activated after binding via CARD-domains to the apopto-
some, a holoenzym consisting of seven Apaf-1 molecules formed after interaction with 
cytochrome C released from the mitochondria.  
While the catalytic activity of initiator caspases follows binding and cleavage at initiation 
complexes (DISC and apoptosome), executioner caspases exist constitutively as 
homodimers and require proteolytic cleavage of an initiator caspase for activation [75]. 
The downstream substrates of executioner caspases are kinases, enzymes of the DNA-
repair machinery and proteins involved in DNA-replication and splicing [66]. Caspases 
are catalytically active and even caspase precursors contain a small amount of catalytic 
activation, but are both kept in check by anti-apoptotic regulators. 
 
2.1.3 Regulators of caspase activity and apoptosis 
Cell death in terms of apoptosis is a central process for an organism. Therefore, mecha-
nisms are needed to control the core of the apoptotic machinery represented by caspases. 
The activity of caspases is governed by a variety of regulators. 
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FLIP-isoforms 
A group of molecules able to modulate caspase-8 activity upstream of the apoptosis 
pathway are the cellular FLICE- inhibitory proteins (cFLIP). Different variants of cFLIP 
exist. At the protein level, three isoforms have been detected so far: cFLIPL, cFLIPS and 
cFLIPR [17]. All of them contain two DEDs which resemble the N-terminal part of cas-
pase-8 and enable binding to the DISC [36]. 
However, the C-terminus of cFLIPL is longer than the one of cFLIPS and cFLIPR and 
similar to the structure of caspase-8, but lacks caspase activity. Still, the long variant is 
able to form heterodimers with caspase-8 and can be cleaved to p43cFLIP [17], whereas 
the two short variants, cFLIPS and cFLIPR, both compete with caspase-8 for binding of 
FADD. Both, the long and the short variants cFLIPL and cFLIPS can protect cells from 
apoptosis induced by CD95, TNFR1, TRAILR1, TRAILR2 and DR3 due to competition 
with caspase-8 for binding sites. Also, the cFLIPR-isoform has been reported as anti-
apoptotic component acting similar to cFLIPS with regard to apoptosis. 
The role of c-FLIPL has been discussed controversially to be anti-apoptotic at high con-
centrations [20] [56] or pro-apoptotic at low concentrations [20]. A recent study of 
Fricker et al. experimentally and theoretically revealed that not solely the amount of c-
FLIPL, but receptor stimulation influences the pro- or anti-apoptotic effects of c-FLIPL 
[36]. It has also been proposed earlier, that relative levels of cFLIPL and cFLIPS poten-
tially determine a crucial balance of caspase activation and NFκB-signaling, the latter 
associated with survival [17]. 
 
IAPs (inhibitors of apoptosis) 
A family of proteins both preventing activation of caspases as well as inhibiting catalyti-
cally active caspases are IAPs (inhibitors of apoptosis). Characteristic for this group of 
apoptosis inhibiting molecules are BIR (baculoviral IAP repreat) domains which are es-
sential for their anti-apoptotic effect. Eight human IAPs have been identified so far [84], 
out of which XIAP is the best characterized protein and also the most potent inhibitor of 
cell death in vitro [18]. XIAP binds to the active-site pocket of effector caspase-3 and -7 
via its linker region located between its BIR1 and BIR2 domains. In that way, the binding 
of substrate to caspase is blocked.  
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Inhibition of caspase-9 is achieved by a different strategy. Here, XIAP binds via its BIR3 
domain to caspase-9 homodimerization surface and hence prevents caspase-9 from form-
ing a catalytically active molecule [69]. 
    
Bar (Bifunctional inhibitor of apoptosis) 
Another molecule able to interact with caspase-8 is Bar (bifunctional apoptosis regulator). 
Bar contains a DED domain and is reported to sequester and inhibit active caspase-8 
hence it prevents further caspase cleavage and apoptosis [88].  
In addition to a DED, Bar includes a zinc-binding RING (really interesting new gene) 
domain, a TM (transmembrane) domain and a SAM (sterile alpha motive) domain. The 
SAM domain is required for interactions with Bcl-2 family members and apoptosis sup-
pression [98]. Thus Bar represents a protein able to interfere with components of the ex-
trinsic and intrinsic pathway and is suggested to interrupt the amplification loop of cas-
pase-8 via the Bcl2 family member Bid [81]. 
 
2.1.4 The Bcl-2 family 
Mitochondrial outer membrane permeabilization (MOMP), the central event of the intrin-
sic apoptotic pathway, is considered the “point of no return” of apoptosis [22]. It involves 
cytochrome C and Smac release from mitochondria, components required for apoptosome 
formation and XIAP inhibition, both promoting caspase activation. Hence, careful control 
of MOMP is important and it is regulated by proteins of the Bcl-2 (B-cell 
CLL/Lymphoma 2) family [38] [97]. The Bcl-2 family can be categorized into three sub-
groups with regard to their structural elements and function during apoptosis: The anti-
apoptotic members (BCL-2, BCL-XL, BCL-w, A1, MCL1), the pro-apoptotic Bax-family 
(BAX, BAK, BOK) and the pro-apoptotic BH3-only family (BID, BIM, BIK, Bad, BMF, 
NOXA, PUMA) [75]. Structurally, the categorization into the subgroups is based on the 
number and type of BH-domains (Bcl-2 homology domains). 
Anti-apoptotic members contain BH1-BH4 domains and can form a hydrophobic groove 
that enables interaction with the BH3 domain of a BH3-only protein. The anti-apoptotic 
BCL2 members, also known as guardians of mitochondrial integrity, have been shown to 
be potent inhibitors of cell death. 
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In contrast, molecules of the BAX-family are called ‘effector molecules of the BCL-2 
family’. They are widely believed to act on the mitochondrion and to induce permeabilza-
tion of the outer mitochondrial membrane triggering the release of intermembrane space 
proteins like cytochrome c [62]. The BAX-family members contain the BH1-BH3 do-
mains. Murine cells that lack BAX and BAK fail to undergo MOMP and show resistance 
to several apoptotic stimuli [75] which indicates that the presence of BAX and BAK is 
needed to release cytochrome-c.  
However, BH3-only proteins are not able to induce cell death in the absence of BAX and 
BAK and therefore clearly act upstream of the effector molecules [21].  
The proteins BID and BIM of the BH-3-only family are considered direct activators of 
BAX and BAK via a transient interaction [23]. After cleavage of BID by caspase-8 to 
tBid [64] [65] and translocation to the mitochondria, it interacts with other BCL2-family 
members in order to enhance pro-apoptotic signaling [87]. The BH3-only protein Bid 
therefore is regarded as a mediator of the extrinsic and intrinsic apoptosis pathway. BID 
was also identified to interact with both BAX and BCL-2 and is associated with a higher 
cell death rate if abundantly present [94]. BAX was identified to interact with BCL-2 as 
well. Moreover, the ratio of BAX to Bcl-2 was found to increase cell death rate, with high 
BAX in relation to BCL-2 accelerating cell death [74]. 
Due to this and further findings, the balance between pro- and anti-apoptotic BCL-2 pro-
teins have been suggested to determine cell fate [23] [74].  
Nevertheless, the exact mechanisms of inhibition and activation of BCL-2 proteins for 
guarding or disrupting the mitochondrial membrane are not yet fully understood [62] 
[23]. 
 
2.1.5 PARP 
Poly(ADP)ribose polymerase-1 is a nuclear protein involved in DNA repair. The N-
terminal region of PARP-1 bears a DNA binding domain (DBD) of two zinc fingers that 
are necessary for recognition of DNA single and double strand breaks. 
Binding to DNA strand breaks is followed by conformational change leading to catalytic 
activity of PARP-1 [14]. Activate PARP-1 catalyses the cleavage of NAD+ (nicotinami-
dadeninenukleotid) into nicotinamid and ADP-ribose. The latter is then attached to nu-
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clear proteins including histones and PARP-1 itself leading to chromatin structure relaxa-
tion enabling the access to the damaged site for repair enzymes [48]. 
During apoptosis, it is specifically cleaved by effector caspases resulting in two fragments 
of 89 and 24 kDa [19] and this is considered as an indicator for apoptosis [58]. PARP 
fragments can therefore be used for detection of apoptosis in various cell types [55]. 
 
2.2 Apoptosis and cancer 
The complex interplay of pro-and anti-apoptotic molecules of the apoptosis signaling 
network governs cell fate decisions. The alternative expression for apoptosis, “pro-
grammed cell death” indicates an orchestrated fashion of molecules to collaboratively 
trigger a cell’s destruction. In fact, perturbed molecule interactions can crucially affect 
cell fate leading to either abundant or reduced apoptosis as observed in various diseases. 
In the case of cancer, too little apoptosis takes place [61]. 
The strategy of a healthy organism is to terminate cells with irreparable damage. This is 
considered a very efficient way to protect against tumor development since malignancies 
arise rarely with regard to the total number of cell divisions occurring during a lifetime 
[69] [42]. However, tumor cells have acquired the ability to inhibit or evade apoptosis 
which is also considered as one of the hallmarks of cancer [42]. Yet, in case the inhibition 
is restored, it has been reported that apoptosis can be triggered again [69]. Hence, the 
components of the apoptosis pathway represent promising points of efficient drug inter-
vention [1]. For various cancer entities, different anti-apoptotic proteins are over-
expressed and pro-apoptotic proteins down-regulated [27]. Table 2.1 gives an overview of 
pro- and anti-apoptotic components and their role in different types of cancer. 
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Table 2.1 Apoptotic pathway components perturbed in cancer 
Perturbations of pro- and anti-apoptotic pathway components inhibiting cell death are observed in clinical 
phenotypes of cancer. Malignant cells have developed strategies for survival e.g. by over-expression of 
anti-apoptotic proteins and inactivation of pro-apoptotic proteins. 
Proapoptotic Components Perturbation in Cancer Examples 
Bax Mutation Hemic malignancies, colon 
carcinoma 
Death-receptors Deletion/mutation Head and neck cancer 
  Reduced expression Hepatocellular carcinoma, 
melanoma, lymphoma 
Caspases Deletion Lung carcinoma, neurob-
lastoma  
  Reduced expression Lymphoma 
Bad Hyperphosphorylation Various malignancies 
Apaf-1 Reduced expression Human leukemic blast 
cells, bladder cancer 
  Inactivation Malignant melanoma 
TRAIL-receptor1/2 Mutation Metastatic breast cancer 
Cytochrome C Inhibited relase from mitochondria Various malignancies 
      
Antiapoptotic Components Perturbation in Cancer Examples 
Bcl-2 Chromosomal translocation Follicular lymphoma 
  
Overexpression Breast carcinoma, gastroin-
testinal carcinoma 
c-FLIP Overexpression Lymphoma, pancreas car-
cinoma, melanoma 
IAPs Chromosomal translocation Marginal zone lymphoma 
  
Overexpression Melanoma, neuroblastoma, 
breast and colorectal carci-
noma 
Kinases Down-regulation of PI3K-
inhibitor PTEN 
Glioblastoma, melanoma, 
prostate carcinoma 
  Overexpression Ovarian carcinoma 
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3 Methods for analysing biological systems 
Research of biological systems has been pursued in various ways. High-throughput meth-
ods for measuring omics data fostered data-driven approaches based on statistical meth-
ods for hypothesis generation. Statistical methods for data analysis of large scale or even 
genome-wide data generally identify single components, groups of genes or proteins as-
sociated with a certain phenotype. However, to understand cellular functions and how 
they arise from molecular interplay as a system, fundamentally different computational 
methods are required to examine structure and dynamics of molecule interactions. This 
chapter will give an overview of current methods, their underlying ideas, advantages and 
limitations. 
 
3.1 Gene expression profiling 
High-throughput gene expression profiling by microarrays enables data acquisition on a 
large scale by measuring thousands of genes at once and therefore allows the study of 
biological systems on a genome-wide level. Genes can be considered as the units of in-
formation for long-term storage within a cell which encode for proteins. Transcription is 
the process by which this information is used to synthesize a gene product, in this study a 
protein. To this aim, a gene’s DNA sequence is first transcribed into mRNA which is then 
translated into a sequence of amino acids required by a functional protein. Gene expres-
sion can be regulated on different levels: By varied transcription, RNA splicing and si-
lencing, translation and post-translational modifications of proteins. However, the levels 
of mRNA represent at the transcriptional level the activated genes and hence the relative 
amounts of protein that a cell is supposed to produce.  
By means of microarrays, relative abundances of mRNA transcripts can be measured.  
For a microarray experiment, RNA extracts taken from the tissue of interest are ampli-
fied, fluorescently labelled and hybridized to the microarray, which contains several thou-
sands of spots of complementary DNA probes representing genes. After quantification of 
the fluorescence signal and normalisation, gene expression data is ready for analysis.  
Microarray measurements are widely used to compare samples of different states or 
classes, for example healthy and tumor tissue, in order to find molecular markers as char-
acteristics for a certain phenotype. In particular, differentially expressed genes as single 
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components, patterns of several genes or as a functional group are identified in several 
studies and used in order to classify or further elucidate phenotypes. 
 
3.2 Identification of altered individual molecules  
An easy and intuitive way to compare gene expression data of two phenotype classes is 
calculation of the fold change (FC) expression. The fold change is obtained by calculating 
the mean of a gene expression value for a certain gene gi (or microarray probe) of all 
samples in one phenotype class (e.g. tumor tissue) divided by the mean of the second 
class e.g. control group of healthy individuals: 
 
𝐹𝐶𝑔𝑖 = 𝑚𝑒𝑎𝑛(𝑔𝑖𝑐𝑙𝑎𝑠𝑠)𝑚𝑒𝑎𝑛(𝑔𝑖𝑐𝑜𝑛𝑡𝑟𝑜𝑙) 
 
For genes equally expressed in both classes, the FC equals 1. In case of down-regulation 
of gene i in the group of cases, the FC results in a value between 0 and 1 and in the case 
of over-expression a value exceeding 1 is obtained [54]. This intuitive measure was used 
for the first time for detecting genes in Sacharomyces cerevisiae [29]. 
Various statistical methods exist to detect differentially expressed genes which addition-
ally yield a measure for significance of the finding [49]. However, the calculation of fold 
changes help in spotting interesting genes associated with a phenotype and gives an intui-
tive measure of how much a gene differs on average from measurement in the control 
group. 
 
3.3 Globaltest for testing groups of genes 
Data mining or statistical methods for identification of individual genes result in a list of 
components, which represent a characteristic pattern of genes associated with a certain 
phenotype, but often do not reveal functional dependencies. Databases, ontologies and 
literature help assign the obtained list of components to biological processes, functional 
groups or modules. For a given group of functionally related components, group testing 
methods exist which test for a significant association of the whole set with a phenotype. 
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The use of a group test could be motivated by a question like: Is there a differential gene 
expression between tumor and normal samples for the apoptosis pathway?  
One kind of group tests is a globaltest for groups of genes [40]. This statistical procedure 
tests a global null hypothesis as an intersection of many particular null hypotheses. The 
underlying assumption of a single null hypothesis is that there is no differential expres-
sion for a specific gene. The assumption corresponding to the global null hypotheses is 
that all single null hypotheses are true. For a gene set of k genes, the globaltest is the in-
tersection of all k individual null hypotheses. In case the global null hypothesis is re-
jected, the data provides evidence, that the selected gene set shows a different behaviour 
between the two observational classes. In the case of the globaltest presented by Goeman 
et al. [40] a significant association between a gene set and phenotype classes is identified 
by linear modeling. The globaltest results in a p-value for the whole group instead of a 
single gene and indicates significance of association as well as the ability to predict a 
phenotypic class using the group of genes. 
 
3.4 Introduction to systems biology 
Present-day systems biology aims at understanding biological systems, for example cells, 
and how their functions arise from the interplay of their components. It involves examina-
tion of structure and dynamics of molecule interactions as a whole, rather than isolated 
parts of a cell [52]. According to Westerhoff and Palsson, two lines of investigation led to 
contemporary systems biology. One of them starts from identification of individual mole-
cules and aims at up-scaling to a simultaneous view on all molecules and their interac-
tions. The second line originates from non-equilibrium thermodynamics and focuses on 
the formal analysis of new functional states arising from molecule interactions aiming at 
the discovery of general principles rather than being descriptive [95]. 
Based on these two lines of systems biology, two different approaches exist: Top-down 
and bottom-up approach. Top-down systems biology is characterized by the use of poten-
tially complete, that is large, genome-wide data sets for identification of network interac-
tion structures or modules employing phenomenological models. In contrast, bottom-up 
systems biology starts with the parts of the system formulating the behaviour of each 
component and integrating these formulations usually as mechanistic models to predict 
system behaviour [15]. 
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For bottom-up systems biology, model design plays an important role. Focus and aim of 
research determines granularity, scope and formalism used for modeling a certain aspect 
or part of reality. 
 
3.5 Formalisms for modeling molecular interactions 
Modeling of biological processes helps to incorporate existing knowledge about molecule 
interactions. Knowing the interaction structure of a set of functionally related cellular 
components, computational or mathematical models can be constructed. The model repre-
sentation can then be used to simulate the system’s behaviour. Different modeling formal-
isms for describing pathways and their characteristics as a system taking also into account 
the interactions among the components differ in their ability to represent temporal and 
stochastic behaviour as well as in their level of granularity [37]. 
 
Graph representation of molecular interactions 
A simple and intuitive way to represent knowledge about molecules and their interaction 
structure is a graph consisting of vertices and edges. Vertices correspond to molecules 
and edges refer to interactions among the molecules. Graphs enable analysis of the inter-
action structure by graph theoretic approaches. In that way, topological features like con-
nectivity of compounds or network motives can be revealed [26] [93][71]. This kind of 
modeling approach lacks the temporal aspect of molecule interactions and therefore can-
not reflect their dynamic nature. However, a graph representation is often the starting 
point for further studying a network. 
 
Computational and mathematical models 
For a more detailed analysis of pathways, Fisher and Herzinger [35] distinguish between 
computational and mathematical models. Computational models are suitable for pathway 
modeling if precise quantitative relationships or parameters are unknown. Examples for 
computational modeling are Boolean and Bayesian models. 
Boolean models assign values of 1 or 0 to each node, which reflects a molecule’s state in 
terms of on/off or active/inactive. A Boolean function or logic rule takes into account the 
state of the variables at a certain time-point in order to get an evaluation for the next time-
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point. In that way Boolean models enable the study of the causal and temporal relation-
ships on a coarse grained modeling level. 
Another computational method for modeling based on a graph representation is a Bayes-
ian network [37] [53]. While Boolean networks can only handle discrete values, the 
Bayesian formalism can also handle continuous values. Here, a node represents a random 
variable for the conditional probability distribution of each pathway component. Bayesian 
modeling offers the ability to describe stochastic processes and dealing with uncertainty, 
incomplete knowledge and noisy observations. Limitations are the static and acyclic na-
ture of Bayesian networks. 
Another graph-based modeling approach is a Petri-net. Here, the set of nodes consists of 
places representing molecule species and transitions representing reactions. Concentra-
tions of molecules correspond to so-called tokens associated with each place. By firing 
rules, tokens are transferred through the graph from one place to another simulating a flux 
through the network. Originally, Petri nets were restricted to qualitative simulation with 
discrete time steps. However, advanced Petri nets are able to mimic Boolean, Bayesian 
and even systems of ordinary differential equation. 
A system of differential equations enables to describe changes in molecule concentrations 
in a quantitative, time-continuous fashion and therefore it is considered a fine grained 
modeling formalism. Computationally more demanding are partial differential equations 
(PDE) and the chemical master equation (CME), which are applied in case either spatial 
phenomena or stochastic effects of low molecule number fluctuations are of interest.  
However, the common method for representation and simulation of molecular interaction 
network dynamics is a deterministic system of ordinary differential equations (ODEs). 
These equations describe changes in abundance of molecule species, where parameters of 
the system have a physical interpretation like concentration, reaction rate or binding af-
finitiy [5]. Hence, ODEs reflect physical reality of molecule dynamics to a high degree 
with parameters corresponding to experimentally measurable values.   
 
3.5.1 Mathematical modeling of chemical reaction systems 
For modeling a biological process by means of ODEs, the change in concentration of a 
single chemical species xi e.g. (a protein) is described as a function depending on time. 
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During a biological process, several chemical species and reactions are involved. Bio-
chemical reactions can be expressed by reaction equations of the general form [53]: 
 (−𝑠1 )𝐶1 + ⋯+ (−𝑠𝑝) 𝐶𝑝 →  (𝑠𝑝+1 )𝐶𝑝+1 + ⋯+ (𝑠𝑝+𝑞 )𝐶𝑝+𝑞   
 
Here, the components C1,…,Cp are educts and Cp+1,…,Cp+q are products. The stoichiomet-
ric coefficients of the reaction are represented by si, where s1,…,p take negative and 
sp+1…sp+q positive values. 
In case one or more educts interact directly to form products within a single step, this type 
of interaction is called elementary reaction. For an elementary reaction the notion of some 
mechanistic significance between reaction participants (e.g. collision) is assumed [79], 
which is highly improbable for three or more molecules. Therefore, a system of reactions 
is decomposed into elementary reactions in which only one or two educts generate a 
product in a single reaction step. Assuming temperature, pressure and density of the reac-
tion mixture to be uniform, we can define the reaction rate v(t) or velocity of a reaction 
according to the law of mass action to be proportional to the product of involved compo-
nents. Hence the change in abundance per time unit of an elementary reaction can be de-
fined as: 
 
𝑣(𝑡) = 𝑘 � 𝑥𝑖(𝑡)−𝑠𝑖
𝑅𝑒𝑎𝑐𝑡𝑎𝑛𝑡𝑠
 
 
where k is called rate coefficient or rate constant of the reaction, xi the concentration of 
the molecular species C and si the stoichiometric coefficient of the reactant i [7]. Hence, 
the reaction rate v(t) is proportional to the product of components involved in the reac-
tion.  
The temporal change in concentration of xi is then obtained by linear combination of reac-
tion velocities of elementary reactions involved in forming xi multiplied by the 
stoichiometric coefficients sij: 
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𝑑𝑥𝑖
𝑑𝑡
= �𝑠𝑖𝑗𝑘𝑗𝑛
𝑗=1
� 𝑥𝑖(𝑡)−𝑠𝑖𝑗
𝑅𝑒𝑎𝑐𝑡𝑎𝑛𝑡𝑠𝑗
 
 
This statement represents a differential equation expressing the change of concentration 
for one component xi for a matrix of stoichiometric coefficients given by 
 
�
𝑠11 ⋯ 𝑠1𝑛
⋮ ⋱ ⋮
𝑠𝑚1 ⋯ 𝑠𝑚𝑛
� 
 
where m is the total number of chemical entities and n the number of reactions.   
 
3.6 Methods for model analysis 
With a system of differential equations at hand that describes a biological process, explo-
ration and prediction can begin. Execution of ODE-models yield time dependent concen-
trations of simulated molecular species which corresponds to a specific experimental set-
ting. By varying parameters, different settings can be simulated, which can correspond to 
experiments under changed conditions (e.g. changed ligand concentration) up- or down-
regulation and increased degradation or generation of molecules. The output of these pa-
rameter variations in terms of trajectories for changing component concentrations can 
then be visually inspected. 
However, computational methods for model analysis enable us to investigate a model’s 
input-output behaviour in various ways. Methods for model analysis differ in their ability 
to determine qualitative or quantitative, local or global and uni- or multivariate character-
istics of a system’s behaviour. Basic ideas involve the concepts of robustness, stability, 
uncertainty and sensitivity for either maintaining or perturbing a certain process or state. 
Results obtained by analysing a system’s behaviour can be helpful for the modeling proc-
ess (e.g. for model reduction and model specification). The focus in this work however, is 
to discover a model’s interaction structure and how it governs the system behaviour re-
lated to a biological function. Therefore, basic concepts in this section will be explained 
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with regard to how these methods aim at identification of conditions which are important 
for a cellular process. 
 
Qualitative methods 
Qualitative analyses aim at revealing single parameters, regions in parameter space or 
stimulation patterns as system input that lead to changes with regard to steady-states and 
their stability behaviour [8] [32] [63] [70]. In the case of steady states, the partial deriva-
tive with respect to time is not changing i.e. the left hand side of the last equation in sec-
tion 3.5.1 equals zero, which means that molecule concentrations do not change over 
time. 
Linear ODE-models can be solved analytically for steady state solutions. More complex 
models require computational methods which help finding important factors affecting 
steady state behaviour. 
Qualitative methods associate certain steady-states of the system to distinct cellular states 
like death or survival of a cell [8] [32] [9] [63] and assume bistability to be required for 
decision making of a cell. Stability refers to attraction to a steady state due to parameter 
variation. In the case of bistability, the system can alternate between two stable steady 
states similar to a toggle switch [6]. 
Bifurcation analysis can be applied to identify important parameters which affect the 
number of steady states and identify which parameter value is associated with a certain 
state and its corresponding stability behaviour.  
 
Quantitative methods 
In order to determine essential parameters to influence signaling strength, signal duration 
or overall effect of a system’s output, quantitative methods for model analysis are used. A 
widely used quantitative method is sensitivity analysis. It apportions the change in model 
output to the change of model parameters and in that way identifies most influential fac-
tors [67] [83]. Another quantitative method which determines the most important reac-
tions or proteins is control analysis [45], an extension of metabolic control analysis to 
signaling pathways. 
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Global and local methods 
Both qualitative and quantitative analysis can be local or global. Local sensitivity analysis 
focuses on a particular point in parameter space and varies a single parameter at a time to 
detect its effect on the system’s output. Local analyses are easy to implement and inter-
pret and therefore common, but are restricted to one specific point in parameter space and 
further do not account for parameter interactions [30]. Only recently, also global analyses 
are applied to biochemical models. Global procedures involve random sampling of pa-
rameter space to explore the whole range of possible parameter values and its correspond-
ing effects. Since rate constants and molecular concentrations vary in an interactive man-
ner, simultaneous parameter variations as part of global sensitivity analysis should be 
preferred over local methods for investigation of biochemical models. Examples for local 
and global sensitivity analysis applied to biochemical network models can be found in 
[91] and [30]. 
 
Methods to identify multi-parameter effects 
Both, qualitative and quantitative model analysis methods are usually univariate that is 
the change in system behaviour or response is analysed with respect to variation of one 
parameter at a time and identification of single parameters as important factors. However, 
global methods for sensitivity analysis detecting higher order sensitivities are able to cap-
ture possible parameter interactions [30] yet fail to suggest underlying mechanisms. 
An example for detecting interactions of parameters is parameter clustering, which identi-
fies factors depending on a set of parameters, however aims at system identification [11]. 
Control analysis [45] is able to point out important reactions instead of single proteins, 
but fails to explain underlying mechanisms. 
Direct Lyapunov exponent (DLE) analysis can be regarded as an example for capturing 
multi-parameter effects in the sense of investigating how a system governs or controls a 
certain system response by suggesting an explicit mechanism. DLE analysis is a multi-
variate local method for sensitivity analysis able to handle transient signals. It aims at 
finding conditions on component relations resulting in a certain system response. DLE 
analysis however, requires visualisation of the phase space, that is, the set of initial 
chemical species concentrations [4]. For a large model with a high dimensional phase 
space, visual inspection of DLE values can be tedious. 
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Not much work has been done in the field of multivariate model analysis of ODE sys-
tems. Nevertheless, multivariate computational methods for analysis of coupled ODEs are 
highly desirable, since they take into account changes of several parameters to give rise to 
a certain system response and in that way help elucidate intertwined interactions and 
mechanisms at the molecular level. 
Hence, an automated multivariate method for model analysis that takes into account 
changes of several parameters with regard to a certain system response is desirable. In 
that way, intervention strategies involving several co-operating components instead of 
single perturbation points could be identified to cause a certain system outcome. 
 
3.7 Decision trees   
Decision trees originate from two different branches of research. Developed in the field of 
statistics by Breiman et al. [13] as classification and regression trees (CART) in 1984 and 
in the area of artificial intelligence by Quinlan [78] as a method called ID3 in 1986 fol-
lowed by later versions named C4.5 and C5.0, the methodologies differ only slightly and 
share the fundamental concept. The basic idea of a decision tree is to build a classifier 
which partitions the input space 𝑅𝑟 into cuboid regions (see Fig. 3.1A) for predicting an 
output variable Y. The classifier is graphically represented as an acyclic graph (Fig. 3.1B), 
called tree which contains nodes and edges and can be translated into a corresponding 
rule set (Tab. 3.1). 
 
Figure 3.1: Input regions and decision tree representation 
A: The partitioning obtained from a decision tree algorithm corresponds to partitioning 
the input space into regions according to threshold values. Each region is assigned a leaf 
node. B: Graph representation of a decision tree. 
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Table 3.1: Rule set corresponding to decision tree of Fig. 3.1 
Path Rule
[1]  If X2 ≤ θ1 and X1 ≤ θ2 then t1
[2]  If X2 ≤ θ1 and X1 > θ2 then t2
[3]  If X2 > θ1 and X2 ≤ θ3 and X1 ≤ θ4 then t3
[4]  If X2 > θ1 and X2 ≤ θ3 and X1 > θ4 then t4
[5]  If X2 > θ1 and X2 > θ3 then t5  
 
Two different types of nodes are part of a decision tree: decision nodes and leaf nodes. A 
decision node represents a criterion used for testing a variable Xi from a set of variables 
X1, X2,…, XD. A test could be a question like: Is the value of variable Xi lower than θi? 
The decision node at the top of the tree containing only outgoing edges is called root. In 
contrast, a leaf node contains only incoming edges and appears at the bottom of the tree 
representing a class which is associated with a certain partitioning based on a sequence of 
tests. By following a particular path from root to bottom where each edge corresponds to 
a certain value of the variable tested upstream, an item can be classified.  
The decision tree methodology according to Breiman et al. involves growing a maximal 
tree, computing an estimate for the misclassification error, pruning the maximal tree to a 
set of subtrees and choosing the best pruned subtree. The whole procedure is explained in 
detail in the following section.       
 
3.7.1 Construction of decision trees for classification 
The construction of a decision tree requires a labelled data set 
 
𝐿 = {(𝑥1,𝑦1), (𝑥2,𝑦2), … , (𝑥𝑁 ,𝑦𝑁)} 
 
also called historic data, learning sample or training data, where xn is one object or vector 
measured in the input variables X1, X2,…, XD with n = 1,…,N. The measurement vector 
can consist of variables of two general types. Either a variable is numerical in case vari-
able values are real numbers or a variable is categorical in case values of a finite set with-
out any natural ordering can be taken. The object’s corresponding class label is expressed 
by 𝑦𝑛 which can take a value 𝑘 ∈ {1, … ,𝐶}. In case of a binary classification problem, an 
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item can belong to either of two classes i.e. 𝑘 ∈ {1, 2}. The tree classifier is then con-
structed by recursively partitioning of the training data set of measurement vectors into 
“purer” subsets ideally containing vectors of one class. To this aim, every possible value 
of each variable is considered and evaluated to choose the criterion for the best split.  
The goodness of split is evaluated by an impurity function, the gini index in case of 
CART [44][13]: 
𝑖 = �𝑝(𝑘|𝑡)(1 − 𝑝(𝑘|𝑡))𝐶
𝑘=1
 
where p(k|t) is an estimate of the conditional probability that an observation x is in class k 
given that it falls into node t [47], which can be reduced for two classes to 
 
𝑖(𝑡) = 2𝑝(1 − 𝑝) 
 
for p, the proportion of the second class. Since the aim of a good split is to partition the 
data into descendant subsets LL, LR that are more homogenous than the parent subset with 
regard to their assigned class, a split is chosen which yields the largest decrease in impu-
rity i.e. the one that maximizes: 
 
∆𝑖(𝑠, 𝑡) = 𝑖(𝑡) − 𝑝𝐿  ∙ 𝑖(𝑡𝐿) − 𝑝𝑅  ∙ 𝑖(𝑡𝑅) 
 
For pL and pR, the proportions of items that go into the subset LL and LR respectively re-
sulting from a candidate split s. The criterion for splitting is illustrated within the tree 
representation as a decision node. Recursive splitting of the learning sample can be done 
until all items are split into subsets containing only representatives of one class or until a 
certain stop criterion is reached e.g. a minimum number of cases falling into one node.    
In order to evaluate a constructed tree T, the estimate of the resubstitution error at node t 
is defined as 
 
𝑟(𝑡) = 1 −𝑚𝑎𝑥𝑘𝑝(𝑘|𝑡) 
 
and for tree 𝑇 with its set of terminal nodes  𝑇� = {𝑡1, 𝑡2, … , 𝑡𝐿}: 
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𝑅(𝑇) = �𝑟(𝑡𝑙)𝑝(𝑡𝑙)𝐿
𝑙=1
 
with 𝑝(𝑡𝑙), the proportion of all items that fall into node 𝑡𝑙. The resubstitution error can 
be regarded as the error rate on the learning sample. In order to choose a classifier, which 
does not overfit the data, Breiman et al. suggest to grow the full decision tree 𝑇𝑚𝑎𝑥 first 
and then reduce the tree by cost-complexity pruning. This pruning method involves the 
construction of a set 𝑇0,𝑇1, … ,𝑇𝑀 of subtrees of  𝑇𝑚𝑎𝑥 where  𝑇0  =  𝑇𝑚𝑎𝑥  and  𝑇𝑀 is the 
root tree. Subtree 𝑇𝑖+1 is then obtained from  𝑇𝑖 by removing those branches that account 
for the lowest increase in error rate per pruned leave. Let 𝐿𝑇𝑖be the number of leaves of 
𝑇𝑖. A tree T pruned in a node t by removing the branch 𝑇𝑡 which has t as root increases its 
error by the amount 𝑟(𝑡) − 𝑟(𝑇𝑡) and decreases its number of leaves by 𝐿𝑇𝑖−1 . Hence, the 
ratio 𝛼 = 𝑡(𝑡)−𝑟(𝑇𝑡)
𝐿𝑇𝑡−1
 represents the increase in error rate per pruned leave. The tree 𝑇𝑖+1re-
sults from pruning all nodes in  𝑇𝑖 with the lowest value of alpha. 𝑇𝑖 and  𝑇𝑖+1 are charac-
terized each by a certain value 𝛼𝑖 and 𝛼𝑖+1 respectively, with  𝛼𝑖 <  𝛼𝑖+1. Finally, the best 
tree of the set 𝑇𝑚𝑎𝑥(𝛼) = {𝑇0,𝑇1 … ,𝑇𝑀} can be chosen by cross validation. A method 
called n-fold cross validation refers to the procedure of splitting data D into n roughly 
equal parts and use each subset 𝐷𝑖 , 𝑖 ∈ 𝑛, for estimating the performance of a classifier 
that was previously trained on all other data sets 𝐷𝑗 , 𝑗 ≠ 𝑖.     
In the case of decision trees, Breiman et al. suggested as the final classifier the simplest 
subtree that is within one standard error of the subtree yielding minimal misclassification 
cost on the test set.  The resulting tree is then regarded as the tree pruned to the best level 
[13]. Further pruning can be also done in order to obtain a more comprehensible tree and 
hence can be regarded as “trading accuracy for simplicity” [68]. 
Decision trees are very popular in the biomedical regime because of their intuitive, easy 
understandably nature. Some further favourable properties of CART are [90]: 
 
• CART is non-parametric and does not require specification of any functional form 
• CART does not require selection of variables in advance, since the algorithm 
identifies most significant variables and eliminates non-significant 
• CART results are invariant to monotone transformations of its variables 
• CART can easily handle outliers, isolating them into a separate node 
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4 Bridging phenotypes and molecular mechanisms  
Contemporary experimental and computational methods explained in chapter 3 enable the 
analysis of biological systems on different levels. With genome-wide data at hand, it is 
possible to identify single genes and pathways, yet mechanisms at the molecular level 
stay obscure. For investigation of pathway dynamics and molecular mechanisms, dy-
namic modeling and model analysis are needed (Fig. 4.1).  
In order to understand interactions and mechanisms of molecules at a system level in the 
context of tumor development with a focus on apoptosis using gene expression data, two 
main approaches were developed to bridge clinical phenotypes and pathway mechanisms 
which will be explained in the following sections. 
 
 
Figure 4.1: Bridging clinical phenotypes and molecular mechanisms 
Current computational methods enable investigation of individual or groups of genes associated with a 
disease or alternatively investigation of molecular mechanisms. How to bridge clinical phenotypes and 
molecular mechanism by novel computational methods in order to understand cancer on a systems level is 
explained in this chapter. 
 
4.1 Approach 1: From data to model 
The first approach addresses the question: Can gene expression data explain why apop-
tosis is perturbed in cancer? Given gene expression data sets with a putative disruption in 
one class of samples (here cancer) with regard to a pathway governing the process of 
apoptosis, this approach investigates if gene expression data reflect underlying conditions 
for either death or survival and consequently gives rise to a certain system response. 
For this approach, original start values of an ODE-based apoptosis model are scaled ac-
cording to gene expression data from tumor and normal tissue. The employed model was 
developed by Albeck et al. [3] who studied apoptosis by observing the concentration of 
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PARP and its respective time course as an indicator of effector caspase activity. It is has 
been shown that caspase-3 activity follows a dynamic of the form [80]: 
 
𝑐(𝑡) =  𝑓 −  𝑓1 + 𝑒(𝑡−𝑇𝑑)/4𝑇𝑠 
 
Here, c(t) is the amount of substrate cleaved at time t, f is the fraction cleaved at the end 
of the reaction, Td is the delay period between ligand (disposure) and half maximal cleav-
age ( c(t) = 0.5 f ) and Ts is the switching time between initial and complete effector sub-
strate cleavage. A short switching time of less than 30 minutes has been previously asso-
ciated with apoptotic cell death and was calculated based on PARP time courses by Al-
beck et al. [3]. Based on these findings, we calculated delay time Td and switching time 
Ts of PARP trajectories resulting in a system response of component start values scaled 
by gene expression data of tumor and normal samples. 
This first approach is complemented by traditional microarray analysis, both, of single 
genes and the whole set of pathway components by a globaltest. Two different methods 
for scaling start values were applied: Scaling by fold change and scaling per sample. 
 
 
Figure 4.2: Delay time Td and switching time Ts 
Delay time Td and switching time Ts are characteristics of effector caspase-3 activity according to Albeck et 
al [3] and are used in this thesis for analysis of the system output. Td and Ts were calculated based on 
PARP trajectories where a short switching time has been previously associated with apoptotic cell death [3]. 
Figure was taken from Albeck et al. [3]. 
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4.1.1 Method 1: Scaling by fold change  
The motivation for this scaling method was modeling the average difference between 
normal and tumor tissue represented by the fold change of the gene expression values. 
The relative nature of gene expression measurements by microarray data enables the use 
of the data as scaling factors for original start values. Although the fold change is calcu-
lated for each gene separately, an implicit change of molecule relations is assumed to be 
introduced by the scaling. Since most of the original start values of Albeck et al. [3] were 
estimated by using HeLa cells, these original values are considered to represent the class 
“tumor”, and the fold change-scaled values are regarded to represent the class “normal”. 
In case several probes were corresponding to one model component, the median of the 
probe values was calculated to represent the gene’s expression value. In case, a gene ex-
pression value was not measured for a model component, the original start value was 
taken as the initial concentration. As a system response, a trajectory of model component 
PARP was obtained from simulation of scaled start values and compared to the trajecto-
ries arising from the original start values. 
 
 
Figure 4.3: Method 1: Start value scaling by fold changes of gene expression values 
For simulation of the average difference between normal and tumor tissue, the fold change (FC) of gene 
expression values for each model component (C1, C2, C3 …) is calculated. The resulting value (FC(C1), 
FC(C2), FC(C3)) is then used for scaling the original initial concentrations (IC) representing the class “tu-
mor” (T) in order to obtain the initial concentration representing the class “normal” (N). 
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4.1.2 Method 2: Scaling per sample 
In order to avoid averaging of samples of one class and get a more differentiated system 
response, a second scaling method was applied. Here, the molecule relations are scaled 
per sample by keeping one model component to its original start value and scale all others 
in relation to the fixed value. The start value to be unchanged was set for all calculations 
to be the PARP component. Therefore this scaling corresponds to normalisation of each 
sample to the start value of the model component PARP.  
 
 
Figure 4.4 Method 2: Scaling of start values by individual samples 
For scaling original start values using individual samples of the classes tumor (T1,T2,T3…) and normal 
(N1, N2, N3…), gene expression values of each sample were scaled relative to PARP by setting gene ex-
pression of PARP to 100%. In that way scaling factors for model components (C1, C2, C3,…) were ob-
tained and used to calculate start values for every model component by multiplication with the original 
initial concentration (IC) of model component PARP. This procedure enabled apoptosis reflecting compo-
nent relations of individual samples. 
 
4.1.3 Relations of pathway components 
Based on the assumption balanced pro- and anti-apoptotic relations of pathway compo-
nents and threshold mechanisms to be crucial for signal transduction [11], a matrix of 
probe set ratios was constructed for each gene expression data set. To this aim, the ratio 
of each probe intensity to every other probe intensity corresponding to the model compo-
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nents of Albeck et al. [3] within one data set was calculated (pobe X / probe Y). The re-
sult of this ratio was encoded as  
0 in case (probe X / probe Y) < 1 
       1 in case (probe X / probe Y) = 0 
      2 in case (probe X / probe Y) > 1 
In that way, the set of probes reflecting gene expression as features for a class where 
mapped to a new feature space of probe relations. The relative frequencies of {0, 1, 2} for 
tumor and normal samples respectively were then determined and the frequencies of dis-
cretized ratios that deferred the most for the two phenotype classes were identified. 
Intuitively, anti-apoptotic components are expected to be more frequently higher ex-
pressed than pro-apoptotic components in tumor samples, since cancerous cells are as-
sumed to be resistant to apoptosis. 
 
4.1.4 Complementary traditional analysis of gene expression data 
Fold changes were calculated to reveal single genes to be up- or down-regulated and fur-
ther assist to categorize differences between tumor to normal data to either have changes 
rather affecting the intrinsic or the extrinsic parts of the apoptosis pathway. 
Further, a globaltest on the selected probe sets corresponding to the model components of 
Albeck et al. [3] was performed in order to test for significance of this gene set for dis-
criminative gene expression pattern of tumor versus normal data. A p-value below 0.05 
for the tested pathway components will be considered in this study as indicator for sig-
nificant association to the phenotype. The p-value is calculated based on a permutations 
method [39] and can be computed by means of the R package globaltest. 
 
4.2 Approach 2: From model to data 
The second approach tests whether computationally identified conditions are reflected in 
experimental data, which can potentially lead to apoptosis. This approach involves the 
development of a novel multivariate method for model analysis identifying strategies to-
wards reaching a certain system response or cell fate. 
The developed method was applied to two small models, one of them reflecting EGF- 
receptor internalization and the other one representing core pathway interactions for cas-
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pase-3 activation. Since these models have been previously analyzed by different model 
analysis methods, these systems were used for evaluation and comparison of methods. 
Further, two apoptosis models with biological relevance were analyzed. For these sys-
tems, predicted conditions were checked in gene expression data as well as in literature 
with regard to the molecule levels of predicted pathway components to activate or inhibit 
apoptosis. 
 
4.2.1 A novel method to multivariate model analysis 
Given an ODE-model of a biological process, methods for model analysis aim at identify-
ing system inherent properties and parameters that govern a certain system response. 
Since a system’s behaviour is influenced by the intertwined interaction of several compo-
nents, particularly in the case of cellular decision making, a novel multivariate method for 
model analysis that identifies conditions on model parameters controlling the system re-
sponse was developed. The method simulates an ODE-based model representing a bio-
logical process for randomly generated parameter sets and further applies a decision tree 
algorithm for finding patterns in the parameter sets that lead to a certain model outcome. 
The workflow of the method is sketched in Fig 4.4 and comprises five steps: 
 
1. Defining system response classes 
The first step of the method is defining response classes of the model outcome. Since the 
method is applied to systems of signaling pathways, we are interested in a binary outcome 
represented by the classes 0 and 1 for ‘pathway off’ or ‘pathway on’ respectively. Ac-
cording to the shape of the component output trajectory of interest, mathematical criteria 
are defined to classify a system response as either class 0 or 1. Example trajectories repre-
senting activation classes of a pathway for EGF-receptor internalization (see chaper 5) are 
shown in Fig. 4.6. In this case the defined criterion for activation of the component of 
interest is to reach at least 80% of another component amount.  
However, it is important to note, that classification criteria are adapted specifically to the 
analysed model and scientific question. 
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Figure 4.5: A novel method for multivariate model analysis. 
(1): Random initial values for model components are generated and (2) used as input to a system of diffe-
rential equations. (3) The system response as a result from each simulation is classified to a predefined 
criterion in the classes “pathway on” and “pathway off” represented by 1 and 0, respectively. (4) A matrix 
of start value relation is constructed and used for construction of a decision tree (5). The activation classes 
can be associated to a cellular phenotype (6).    
 
 
2. Generation of random initial values 
The underlying assumption for the approach is that molecule abundances influence path-
way activation. Hence, only parameters corresponding to initial values for model compo-
nents that represent molecular species are considered. A matrix of random initial values 
drawn from a probability distribution within considerable ranges is generated, in which 
each column corresponds to a specific component having a non-zero start value at simula-
tion time t0 and each row vector relates to one parameter set of initial values used as input 
to the ODE-system for one simulation run. Model components that require initial values 
are generally un-cleaved and un-complexed molecular species and typically represent 
proteins corresponding to gene products. As a probability distribution, an equal distribu-
tion was chosen. In general, range for sampling took of four orders of magnitude centered 
around original start values. 
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Figure 4.6: Pathway activation classes to categorize a system response 
 
3. Model simulation and classification of generated parameter sets  
Each row of the generated matrix in the previous step is used as input to the model. For 
simulation, the Matlab programming environment with its ODE-solver ode15s was used. 
Resulting output trajectories of interest are then classified according to the predefined 
criteria in step 1. 
 
4. Construction of a matrix of components relations  
The hypothesis, that threshold mechanisms of molecule concentrations are crucial for a 
certain system response motivates the construction of a matrix containing pair-wise start 
value relations based on the matrix of initial values. To this end, for each parameter set, 
the relation of all unordered pairs of non-zero molecule species X and Y was encoded as 
‘0’ in case X_0 < Y_0, as ‘1’ in case X_0 = Y_0 and ‘2’ in case X_0 > Y_0. In that way 
the numerical values of initial conditions are transformed into categorical attributes of a 
parameter set. Since equal values for randomly generated numbers are highly unlikely, 
this procedure comes down to binarization of start value relations used as features for the 
decision tree algorithm.  
 
5. Application of a decision tree algorithm to component relations 
The matrix of component relations together with the class information obtained from step 
3 are then used as training data in a decision tree algorithm that yields a tree representa-
tion of molecule relations leading to a certain system response. For construction of a deci-
sion tree as explained in section 3.7, the algorithm developed by Breiman et al [13] as 
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part of Matlab programming environment was used. The performance of the tree was cal-
culated by using a resubstitution method and a 10-fold cross validation [13] expressing 
the cost of the tree by means of the misclassification error.  
 
An equal number of representatives of both system response classes was selected before 
applying the decision tree algorithm to the parameter sets in order to build an unbiased 
classifier. The method yields an intuitive tree representation of conditions leading to a 
certain system response and was applied to the models explained in chapter five. 
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5 Mathematical models and experimental data 
In this chapter, data sets and mathematical models employed for this study are described. 
Within the first approach, gene expression data sets from different cancer entities 
representing clinical phenotypes with a putative disruption of the apoptosis pathway were 
analyzed and compared to data from normal samples to evaluate their ability to undergo 
apoptosis during model simulation. For this approach, the currently most comprehensive 
model of apoptosis developed by Albeck et al. [3] was simulated with its original start 
values scaled according to the data as explained in section 4.1.1 and section 4.1.2. 
For the second approach, aiming at the discovery of conditions leading to a specific sys-
tem response, four ODE based models of cell signaling were analyzed: A model for 
EGFR internalization, a caspase activation model, an apoptosis model for CD95/Fas-
induced signaling and the comprehensive apoptosis model by Albeck et al. [3]. Condi-
tions predicted based on the apoptosis models were checked in literature, in case of the 
latter model, also gene expression data was analyzed with regard to predicted conditions. 
 
5.1 Data sets and gene expression data analysis 
Eight gene expression data sets from six different cancer entities (Table 5.1) all of them 
measured on one of the Affymetrix platforms (hgu133a, hgu95 or hgu95av2) were ana-
lyzed. Each of the data sets was normalized by vsn [46] and probes corresponding to 
apoptosis model components of Albeck et al. [3] were selected. 
 
 
 
 
 
 
 
 
 
 56 
Table 5.1: Gene expression data sets analyzed in for this thesis 
Data Set Tumor Type Samples (T/N) Platform Reference 
OralTongue 
Oral tongue 
squamous cell 
carcinoma 
31/26 HG-U95Av2 Estilo et al.,2009 
Breast Breast Cancer 42/43 HG-U133A GSE15852 
Lung Lung adenocarcinoma 27/27 HG-U133A Su et al.2007 
ProstateSingh Prostate cancer 52/50 HG-U95Av2 Singh et al.,2002 
ProstateErnst Prostate cancer 18/9 HG-U95A Ernst et al.,2002 
CML 
Chronic 
myeloic 
leukemia 
11/10             
(CP)/(BC) HG-U133A Zheng et al.,2006 
HeadAndNeck 
Head and neck 
squamous cell 
carcinoma 
22/22 HG-U95Av2 Kuriakose et al.,2004 
Microdissected Prostate cancer 7/8 HG-U133A Dept. Gröne, dkfz (unpublished) 
 
 
5.2 Mathematical models 
This study focussed on analysing data and models of apoptotic pathway components. 
Two biologically relevant apoptosis models where considered. However, two toy models 
were analysed as well to compare the developed method for model analysis to alternative 
analysis methods. 
 
5.2.1 Comprehensive apoptosis model used for both approaches 
The study of Albeck et al. [3] aims at comprehensively modeling the whole complexity of 
interactions involved in apoptosis including the extrinsic pathway triggered by TRAIL 
ligand and the mitochondria dependent intrinsic pathway. Their extrinsic apoptosis reac-
tion model (EARM v1.0) aims to be complete with respect to biochemical mechanisms 
and contains 58 equations of which 18 species have non-zero start-values. Fig. 5.1 depicts 
the molecule interactions of EARM v1.0. The authors also specified characteristic fea-
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tures based on the PARP component to reflect effector caspase activity and relate those 
characteristics to apoptosis. The characteristic feature as indicator for apoptosis is the 
switching time as explained in section 4.1. The model of Albeck et al. [3] and its parame-
ters specified in the original publication was used in this work for both approaches as 
presented in chapter 4. Detailed information about model components is given in the ap-
pendix.   
 
 
Figure 5.1: Molecule interactions of comprehensive apoptosis model (EARM v1.0) 
The model, EARM v1.0 developed by Albeck et al. was used to study mechanisms during apoptosis  
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5.2.2 Models used for the evaluation of the second approach: 
a) EGFR-internalization model 
In order to test the developed method for model analysis explained in section 2.3, a model 
of EGF-receptor internalization developed by Schmidt-Glenewinkel et al. [85] was used, 
where an analytical solution was derived by the authors and therefore the performance of 
the developed model analysis method could be evaluated.  
The EGFR-model contains a well known motive for competitive binding [16] which has 
been adapted and formulated for investigation of the sorting mechanism of the EGF-
receptor into two different internalization pathways by Schmidt-Glenewinkel et al [85]. In 
this model, the ligand activated receptor can be internalized either via the clathrin de-
pendent pathway (CDE) or the clathrin independent pathway (CIE). 
The model consists of seven molecular species of which the ligand, the receptor and two 
adaptors abbreviated by CDE and CIE require an initial value greater than zero. Upon 
ligand activation, the EGF-receptor component either internalizes via the clathrin-
dependent pathway (CDE-pathway) or the clathrin-independent pathway (CIE-pathway), 
resulting in the model components L:R:CIE and L:R:CDE as the most downstream com-
ponents (Fig. 5.2)  
 
 
Figure 5.2: Schematic representation of EGF-receptor internalization pathways 
 
 
 59 
b) Caspase-3 activation model 
For comparison of a related multivariate method, called direct Lyapunov exponent (DLE) 
analysis and its results with the developed method applying decision trees for model 
analysis, a model for caspase activation was analyzed. This model consists of eight com-
ponents and was investigated for conditions leading to apoptosis caused by high caspase-
3 activation by Aldridge et al. [4]. 
The caspase model contains eight molecular species including pro-apoptotic procaspase-
3, caspase-3, procaspase-8 and caspase-8 and pro-survival factor XIAP as well as three 
intermediate products (Fig. 5.3). 
 
 
Figure 5.3: Network topology of caspase-3 activation model 
 
c) CD95-mediated apoptosis model 
CD95-mediated apoptosis has been studied experimentally and mathematically by simu-
lation of several models [11] [73] [36]. The study of Neumann et al. focused on the 
crosstalk of the CD95-mediated extrinsic apoptosis with NFκB-pathway activation by 
upstream formation of p43-FLIP (Fig. 5.4). The ODE-based model was regressed to 
quantified western blot time series data and consists of 23 equations, eight of which rep-
resent molecular species with non-zero initial values including pro-apoptotic components 
represented by caspase-3 and -8 as well as two different species of cFLIP-isoforms previ-
ously associated with inhibition of apoptosis [60].    
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In order to predict biologically relevant relations of a well studied aspect of the apoptosis 
pathway, we applied our decision tree approach for model analysis to the model of Neu-
mann et al. [73]. This model was chosen for analysis, since it has a reduced number of 
components focussing on the essential part of CD95-mediated apoptosis and NFκB acti-
vation, but still reflects experimental data well [73]. Due to the reduced number of com-
ponents representing a experimentally and computationally well studied network, we ex-
pect our method for model analysis to predict biologically relevant relations of only few 
molecules deciding on cell fate. 
 
 
Figure 5.4: Network topology of CD95/Fas mediated apoptosis model 
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6 Results  
Previous to data and model analysis, model components representing un-cleaved, un-
complexed proteins which correspond to a certain gene were mapped to their correspond-
ing probe identifiers, EntrezGene identifiers and symbols as listed in Fig. 6.1. Here, iden-
tifiers and symbols for caspase genes correspond to the protein procaspases.  
 
Table 6.1: Model components and corresponding symbols, names and identifiers 
Component
Gene symbol 
(Entrez Gene) Official Name (Entrez Gene) Gene ID
TRAIL-R1/DR4 TNFRSF10A tumor necrosis factor receptor superfamily, member 10a 8797
Flip CFLAR CASP8 and FADD-like apoptosis regulator 8837
Procaspase 8 CASP8 caspase 8, apoptosis-related cysteine peptidase 841
Bar BFAR bifunctional apoptosis regulator 51283
Procaspase 3 CASP3 caspase 3, apoptosis-related cysteine peptidase 836
Procaspase 6 CASP6 caspase 6, apoptosis-related cysteine peptidase 839
XIAP XIAP X-linked inhibitor of apoptosis 331
PARP PARP1 poly (ADP-ribose) polymerase 1 142
Bid BID BH3 interacting domain death agonist 637
Bcl-2 BCL-2 B-cell CLL/Lymphoma 596
Bax BAX BCL2-associated X protein 581
Cytochrom C CYCS cytochrome c 54205
Smac DIABLO diablo homolog (Drosophila) 56616
Procaspase 9 CASP9 caspase 9, apoptosis-related cysteine peptidase 842
Apaf-1 APAF apoptotic peptidase activating factor 1 317
TRAIL TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 8743  
 
6.1 Perturbation of individual genes 
We first investigated which single genes are over- or under- expressed in tumor samples 
compared to normal samples. To this aim we analysed each of the eight gene expression 
data sets for the fold change of every probe corresponding to a model component. Some 
components are represented by several probes, hence Fig. 6.1 contains repeated labels. In 
the OralTongue data set (Fig. 6.1 A), the fold change value of TRAIL ligand (TNFSF1) is 
four fold over-expressed. Also pro-apoptotic BAX is double as strongly expressed in tu-
mors compared to normal samples. In contrast, the fold change (FC) of all anti-apoptotic 
Bcl-2 probe sets are slightly lower than 1. The remaining FC-values are in the range of 
0.9 to 1.4. 
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All fold changes of the BreastCancer data set are close to 1 and therefore regarded as not 
differentially expressed. FC-values of procaspase-3, cytochrome C and some probe sets 
corresponding to the ligand are exceeding 1.2 (Fig 6.1 B).  
In case of the Lung data set (Fig. 6.1 C), genes for TRAIL ligand (TNFSF10), Flip 
(CFLAR) and one of the Bcl-2 probe sets is lower expressed in tumors than in normal 
samples, while PARP and cytochrome C are over-expressed (FC = 1.26 and FC = 1.5 
respectively). 
The probe sets of the ProstateSingh data set (Fig. 6.1 D) are mostly balanced between 
tumors and normal samples. Ligand TNFSF10 and cytochrome C however, are over-
expressed in tumors (FC = 1.5 and FC = 1.25, respectively). 
Prostate cancer patients in the ProstateErnst data set (Fig. 6.2 E) show a Bax up-
regulation (FC = 1.4) for the same probe set as identified in the OralTongue data set. 
Most other probe sets are within a range of 0.8 to 1.2. Furthermore, a slight reduction of 
one of the BCL-2 probe sets can be observed in tumor. 
CML patients in blast crisis (Fig 6.2 F) have higher gene expression values for TRAIL 
(TNFSF10), procaspase-8, PARP, Bax and BCl-2 (probe set ID: 203685_at) with FC-
values of about 1.5. Another characteristic of this data set is a high variability (FC of 0.6-
1.15) of Flip fold changes (CFLAR). 
In the case of the Head And Neck data set, procaspases are slightly over-expressed (FC = 
1.2), and PARP is up-regulated (FC = 1.4) in tumors. Higher fold change values of 1.4 
and 1.5 were are observed for Bax probes (Fig. 6.2 G). 
The Microdissected data set (Fig. 6.2 H) shows FC-values close to 1 for all probes, except 
for Bcl-2 (probe set ID: 203685_at), which is reduced by almost 50% reduction in tumor. 
In summary, the fold changes of all data sets are not considered as highly up- or down-
regulated, since most FC-values are in a range between 0.8 and 1.6. Only few exceptions 
are exceeding this range: down regulated probes below a fold change of 0.8 are found in 
the Lung data set for TRAIL-L (FC = 0.48) and CFLAR (FC = 0.65), the latter corre-
sponding to the homologues of the FLIP-family. Within the CML data set, CFALR (FC 
values of 0.6 and 0.75) and Bcl-2 in Prostate Microdissected (FC= 0.55) are found to be 
below 0.8. The only component considered as strongly over-expressed in tumor samples 
is ligand TRAIL-l (TNFSF10) with a FC-value of 4.5 in the OralTongue data set. 
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Figure 6.1: Fold changes of gene expression data A-D  
A: OralTongue, B: Breast, C: Lung, D: ProstateSingh 
 64 
  
 
Figure 6.2: Fold changes of gene expression data E-H 
E: ProstateErnst; F: CML ; G: HeadAndNeck ; H: Microdissected 
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6.2 Apoptosis pathway association with disease state 
By means of the globaltest, the ability to classify phenotypes based on model components 
as a set of genes is tested. P-values below 0.05 are considered as significant. Hence, an 
association with the group of genes listed in Table 6.1 to the phenotype can be assumed 
for the gene expression data sets: OralTongue, BreastCancer, Lung and ProstateSingh 
(Table 6.2). 
 
Table 6.2 Data sets and respective p-values resulting from a globaltest 
The globaltest analyzes sets of genes towards their ability of distinguishing phenotypes and yields a p-value 
as significance measure for the association of the tested group of genes with a phenotype or class. The se-
lected apoptosis components tested for data sets OralTongue, BreastCancer, Lung and ProstateSingh result 
in a p-value of below 0.05. Hence for these data sets, the apoptosis components are regarded as significantly 
associated with the clinical phenotype. 
Data Set p -value
OralTongue 1.1942 ∙10-7
Breast 1.336 ∙ 10-5
Lung 0.78422 ∙ 10-3
ProstateSingh 0.94492 ∙ 10-3
ProstateErnst 0.05303
CML 0.061471
HeadAndNeck 0.17882
Microdissected 0.48811  
 
6.3 Approach 1: From data to model 
The assumption for this approach is that tumor cells are more resistant to apoptosis and 
have developed strategies to survive, in contrast to normal cells, which are supposed to be 
more sensitive to death stimuli. The PARP trajectory as output signal of the model of Al-
beck et al. [3] is therefore assumed to have an earlier or steeper decline for scaling start 
values according to normal samples.  
In the following, only figures according to the OralTongue data set are shown. Results for 
all other data sets were similar. Moreover, the globaltest applied to the OralTongue data 
set resulted in the lowest p-value of all given gene expression data sets. However, differ-
ing results and peculiarities of certain data sets are noted in this chapter and figures for all 
data set can be found in the Appendix A. 
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6.3.1 Results for start values scaled by fold change 
Each of the eight data sets listed in Tab. 5.1 was used separately for scaling original start 
values according to tumor and normal data. Time courses of the PARP component result-
ing from original start values representing the class “tumor” and scaled start values repre-
senting the class “normal” as illustrated in Fig 6.3 were visually inspected. 
PARP start values after scaling were for most data sets lower than original values and 
resulted in a delayed response while steepness of the time courses and switching time Ts 
were similar for all data sets. Scaling according to the data set ProstateErnst yielded a 
slightly higher initial value for PARP but still resulted in a delayed response. The Lung 
data set resulted in a lower concentration for PARP and in a slightly earlier response (Ap-
pendix A). 
However, the scaling of original start values by the fold change did not yield qualitatively 
different trajectories for the PARP component with regard to Ts as indicator for apoptosis, 
even when start values were much higher or lower after scaling. 
 
Figure 6.3: PARP trajectories resulting from fold change scaling 
PARP trajectories shown for original start values in black and for fold change scaled values representing the 
class “normal” in green as a result of the OralTongue data set. 
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6.3.2 Results for start values scaled per sample 
Scaling per sample was introduced to avoid averaging of samples of one class and get a 
more differentiated system response according to individual samples. However, the ob-
tained system response does not show a clear separation of the PARP time courses result-
ing from scaling per sample with regard to the classes tumor and normal as illustrated in 
Fig. 6.4 for OralTongue data. 
 
 
Figure 6.4: PARP trajectories resulting from scaling per sample 
Start values were scaled according to microarray data of normal samples (green) and tumor samples (red). 
 
 
Table 6.3: Td and Ts of PARP time courses for gene expression data sets 
Median values for Td (delay time) and Ts (switching time) calculated as characteristics of PARP trajectories 
resulting from scaling according to normal samples (N) and tumor samples (T). 
Data set
Td median N 
(minutes)
Td median T 
(minutes)
Ts median N 
(minutes)
Ts median T 
(minutes)
OralTongue 22 23 8 8
Breast 342 339 122 159
Lung 491 459 552 450
Prostate Singh 13 14 4 4
Prostate Ernst 41 31 17 12
CML 216 200 77 50
HeadNeck 40 43 17 20
Prostate Microdiss 360 300 602 285  
 68 
Calculation of median values of delay and switching times with regard to the system re-
sponse of each class were performed and showed only minor differences (see Table 6.3, 
compare column 2 to column 3 and column 4 to column 5). 
 
6.3.3 Relations reflected in gene expressions 
The encoded relations of model components were ranked according to their relative fre-
quencies observed for the phenotype classes (tumor/normal) as explained in section 4.1.3. 
The top 20 component relations of data sets yielding p-values below 0.05 for the global-
test are listed in Tab. 6.4. Ranking of relations for the remaining data sets are presented in 
the Appendix A. Generally, for all analysed data sets, in case a pro-apoptotic and an anti-
apoptotic component form a relation, the pro-apoptotic gene is found to be higher ex-
pressed than the anti-apoptotic components in tumor samples (Tab. 6.4). This appears to 
be counter-intuitive, since it suggests tumor cells to be more sensitive to apoptosis. Only 
gene expression data from breast cancer show one anti-apoptotic component (BFAR) in 
tumor compared to normal to exceed the expression level of a pro-apoptotic component 
(caspase-8). 
These results agrees with the finding of Stegh et al. [88] who showed that BFAR inhibits 
caspase-8 in the breast cancer cell line MCF-7 and thus prevents the cleavage of Bid and 
caspase-3. Hence caspase-8 exceeding BFAR in the breast cancer data set suggests that 
the identified molecule relation contributes to apoptosis resistance. 
Furthermore, PARP levels are found to exceed pro-apoptotic components in tumor, but 
are in this work not considered to contribute to a death or survival decision, since it is the 
most downstream protein in the model used. 
 
 
 
 
 
 
 
 
 69 
Table 6.4: Pair-wise relations of apoptosis components in gene expression data 
Orange background: Relation more often found in tumor, light green background: Relation more often 
found in normal, Red font: A pro-apoptotic component, Dark green font: A pro-survival/anti-apoptotic 
component, Blue circle: Only relation were an anti-apoptotic component is higher in tumor samples than a 
pro-apoptotic component on gene expression level. Same gene symbols within one relation refer to different 
probe set IDs of the microarray. 
 
Pos. OralTongue Breast Lung Singh2002
1 TNFSF10 < BAX CASP8 < PARP1 TNFSF10 < CYCS TNFSF10 < BAX
2 TNFSF10 < BCL2 CYCS < APAF1 CFLAR < PARP1 BCL2 < BAX
3 TNFSF10 < BCL2 TNFSF10 < CFLAR CASP3 < BCL2 TNFSF10 < BCL2
4 TNFSF10 < CASP8 TNFSF10 < XIAP TNFSF10 < CASP8 TNFSF10 < BAX
5 TNFSF10 < PARP1 CFLAR < CYCS CFLAR < PARP1 TNFSF10 < PARP1
6 TNFSF10 < PARP1 CYCS < APAF1 CASP6 < BCL2 TNFSF10 < BCL2
7 BAX < BAX PARP1 < CASP9 BCL2 < BCL2 TNFSF10 < CASP9
8 TNFSF10 < CFLAR CFLAR < BCL2 TNFSF10 < PARP1 TNFSF10 < BID
9 BCL2 < BAX CFLAR < CFLAR TNFSF10 < BID CFLAR < BCL2
10 TNFSF10 < BAX CFLAR < CYCS TNFSF10 < PARP1 TNFSF10 < BAX
11 BID < BCL2 CFLAR < BCL2 CFLAR < PARP1 CFLAR < CYCS
12 PARP1 < BAX TNFSF10 < CFLAR CFLAR < BFAR TNFSF10 < CASP8
13 CASP3 < BCL2 TNFSF10 < CFLAR CFLAR < CASP6 TNFSF10 < BCL2
14 TNFSF10 < BAX CFLAR < CFLAR CFLAR < CASP9 CFLAR < BCL2
15 CASP8 < BAX CASP8 < BFAR CFLAR < BID TNFSF10 < PARP1
16 BCL2 < BAX CASP8 < CYCS CFLAR < CASP9 TNFSF10 < BCL2
17 CASP3 < APAF1 BCL2 < CYCS CFLAR < CASP9 TNFSF10 < CASP9
18 CASP8 < BCL2 CFLAR < APAF1 CFLAR < BID CYCS < CASP9
19 BCL2 < BAX TNFSF10 < CFLAR CFLAR < PARP1 PARP1 < BAX
20 CFLAR < BAX PARP1 < CASP9 BID < BCL2 BID < BCL2  
 
6.3.4 Complementary analysis 
The simulation results did not show remarkably different system responses. In contrast p-
values lower than 0.05 of the data sets OralTongue, Breast, Lung, ProstateSingh (Tab.6.2 
and Tab 6.3) resulting from a globaltest indicated significance although most fold change 
values were close to 1, within a range of 0.8 to 1.6.  
By visual inspection, fold change plots (see Figures 6.1 and 6.2) were analyzed and com-
ponents were identified that are up- or down-regulated the most. Only few exceptions are 
exceeding the fold change range between of 0.8 and 1.6: 
The ligand TRAIL-L with a fold change of about 4.5 is exceptionally over-expressed in 
tumor samples of the OralTongue data set. Down-regulated probes below a fold change of 
0.8 are found in the Lung data set for TRAIL-L (fold change of 0.48) and CFLAR (fold 
change of 0.65), the latter corresponding to homologues of the Flip-family. Within the 
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CML data set, CFLAR (fold changes of 0.6 and 0.75), and Bcl-2 in the Microdissected 
data set (fold change of 0.55) are found to be below 0.8.  
Note that fold change values for all data sets identified that most pro-apoptotic compo-
nents are higher expressed in cancer higher than in normal samples, and most anti-
apoptotic pathway components to be lower expressed in normal samples. Exceptions here 
can be observed in the data sets Lung and ProstateErnst where pro-apoptotic procaspase-9 
is down-regulated in cancer. Another exception is up-regulation of anti-apoptotic Bcl-2 in 
CML. 
For some data sets, either the intrinsic or the extrinsic pathway was more likely to be af-
fected, as listed in Table 6.5. Based on expression levels, in the case of prostate cancer 
and head and neck cancer the intrinsic pathway is turned on, whereas in CML rather the 
extrinsic pathway is turned on. Note that here not solely up-regulation of pro-apoptotic 
components, but also down-regulation of anti-apoptotic components is considered. 
 
 
Table 6.5 Inspection of fold change values with regard to apoptotic subpathways 
Visual inspection of the PARP trajectories showed either degradation in one step or stepwise in two steps 
(column 1). Plots of fold changes (FC) showed low differences (0.8-1.5), although yielding a low p-value 
for the globaltest (GT) (column one). Model components which yield higher or lower FC in tumor (T) are 
listed in columns two and three. Also, fold changes for pathway components were found to either affect 
rather the extrinsic (extr.) or the intrinsic (intr.). The arrows (↑ / ↓) indicate subpathway activation of apo p-
tosis in tumor, which not only refers to up-regulation of pro-apoptotic, but also considers down-regulation 
of anti-apoptotic components. Some data sets showed a heterogeneous up-/down-regulation of components 
for subpathways (H). 
Data set GT p-value FC higher in T FC lower in T Patway affected
OralTongue 1.19e-07 L, Bax Bcl-2 Extr. ↑, intr. ↑
Breast 1.34e-05 L, C6, C3 Cyto C Bcl-2 Extr. ↑, intr. ↑
Lung 0.78e-03 Cyto C, PARP L, Flip, C9 Extr. ↓, intr. ↑
Prostate Singh 0.94e-03 L, Cyto C - Extr. ↑, intr. ↑
Prostate Ernst 0.53e-01 Bax, Cyto C C9, Bcl-2, Apaf Intr. ↑
CML 0.61e-01
L, C8, PARP, Bax, 
Bcl-2 Flip Extr. ↑, intr. (H)
HeadNeck 0.18e+00
Bax, PARP, Bid, 
C3/6/8 Bcl-2, Bax Extr. (H), intr. ↑
Prostate Microdiss 0.48e+00 Cyto C Bcl-2 Intr. ↑
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6.4 Generating hypotheses from model analysis: Approach 2 
The developed method for model analysis presented in section 4.2.1 was applied to ODE-
models as explained in section 5.2. In the following, results from using the method to 
predict component relations that trigger pathway activation will be presented. 
 
6.4.1 Decision tree approach can classify parameter sets 
For the small model of EGF-receptor internalization illustrated in Figure 5.2, the pathway 
of interest is the CIE-pathway. In order to find conditions leading to CIE-pathway activa-
tions, the class definition was based on the trajectories of the L:R:CIE- (the ligand acti-
vated receptor internalized via CIE) and the L:R:CDE-component (the ligand activated 
receptor internalized via CDE). The system response was classified as class 1 (pathway 
“on”), in case the L:R:CIE level reaches 80% of the L:R:CDE level at steady state, else 
the CIE-pathway was defined to be not sufficiently activated and classified as class 0 
(pathway “off”). 
 
Figure 6.5: Pathway activation classes of clathrin-independent EGFR-internalization. 
A: L:R:CIE-trajectories (green) and L:R:CDE-trajectories (blue) representing CIE-pathway “off”. 
B: L:R:CIE-trajectories (green) and L:R:CDE-trajectories (blue) representing CIE-pathway “on” 
 
Random initial values were generated for the ligand, the receptor and the two adaptors 
CIE and CDE as specified in Appendix B (Table B1). Out of 10000 generated parameter 
sets, 1808 in total (904 per class) were chosen as input for the decision tree algorithm 
resulting in a misclassification trajectory illustrated in Figure 6.7.  
The misclassification error obtained from the algorithm decreases with regard to the 
number of leave nodes for both training and test by cross validation and suggests a deci-
sion tree containing four leave nodes (Fig. 6.6) as the tree on the best level. This tree 
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yields a misclassification error of 0.06 (Fig. 6.7) which is equivalent to an accuracy of 
94%. For comparison, the decision tree applied to absolute values instead of parameter 
relations is illustrated in Fig. 6.8. Here, a pruning level was chosen with regard to a simi-
lar misclassification error as for the tree in Fig. 6.6. 
 
 
Figure 6.6: Decision tree resulting from model analysis of EGFR-model 
 
Figure 6.7: Misclassification error for decision tree method applied EGFR-model 
 
Although a decision tree applied to absolute parameter values instead of relations can 
classify randomly sampled parameter sets equally well, as the respective error trajectory 
suggests (Fig. 6.9), the corresponding tree (Fig. 6.8) is not easy to interpret. 
R < CDE
L < CDE
CIE < CDE
CIE off
CIE on
CIE off
CIE off
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Figure 6.8: Decision tree applied to absolute parameter values of EGFR-model 
 
 
Figure 6.9: Misclassification error for decision tree of Fig. 6.8 
 
The decision tree using absolute values as features (Fig. 6.8) chooses the components and 
threshold values as nodes which reflect the parameter relations of the tree using compo-
nent relations (Fig. 6.6). However, the decision tree using relations as features structures 
the tree according to the assumption that thresholds of molecule abundances are crucial 
for signaling. This results in a more condensed representation which is easy to interpret. 
CDE<3.47
CDE<0.53
CIE off
CIE on
L<1.50
R<1.54
CDE<0.70 CIE off
CIE off
CIE on CIE off
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6.4.2 Analytically determined solution is reflected in decision tree 
The focus of interest of Schmidt-Glenewinkel et al. [85] was elucidating which conditions 
lead to a switching behaviour of the CIE-pathway. This was done by steady-state analysis 
and parameter scans. Two different steady-state classes were identified which are reached 
depending on the initial values of molecule species leading to either low, medium or high 
number of ligand-activated receptors internalized via CIE-adaptors (Tab. 6.6). 
The system reaches steady-state class I if all free receptors or all ligand molecules get 
depleted and all activated receptors (model component EGF:R) will be internalized [85]. 
This steady state has been associated with no or basal receptor internalization via CIE-
adaptors and is reached in case the initial values of either ligand or receptor is lower than 
the number of CDE-adaptors (condition (S1), Tab. 6.6). 
In order to reach steady state class II, neither the ligand nor the receptor is limiting with 
respect to pathway activation, but both adaptor types are consumed completely. 
This steady state is reached, if ligand and receptor concentrations exceed initial values of 
CDE adaptors leading to a moderate CIE-pathway activation (condition (S2), Tab.6.6). A 
high level of CIE-receptor internalization is reached if ligand and receptor concentrations 
exceed the sum of CIE0 and CDE0 (condition (S3), Tab.1). X0 denotes here the initial 
concentration of component X.  
In order to demonstrate how the conditions found by our method and stated in the deci-
sion nodes reflect the requirements of Schmidt-Glenewinkel et al. [85], we transformed 
the decision tree (Fig. 6.6) into a set of rules where each path from root to a leaf node is 
represented as a rule containing the expressions of each decision node on that path (Tab. 
6.7). 
The top two decision nodes “R0 < CDE0” and ”EGF0 < CDE0” reflected in rule (D1) and 
in the second expression of rule (D2) of Tab. 6.7 indicate that either the ligand or the re-
ceptor level is required to be lower than CDE start concentration to result in an inactive 
CIE-pathway. This directly corresponds to condition (S1) (Tab. 6.6). 
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Table 6.6: Conditions for pathway activation of EGFR internalization via CIE 
Initial values Steady-state CIE-internalization 
 (S1) min{EGF0,R0} < CDE0  I Low 
 (S2) min{EGF0,R0} > CDE0 II Medium 
 (S3) min{EGF0,R0} > CDE0 + CIE0 II High 
 
 
Table 6.7: Decision rules for CIE-pathway activation 
The decision tree obtained from analysis of the EGFR-model was translated into corresponding 
set of decision rues. 
Path  Rule 
(D1)  If R0 < CDE0 then class "CIE off" 
(D2)  If R0 >= CDE0 and L0 < CIE0 then class "CIE off" 
(D3)  If R0 >= CDE0 and L0 >= CDE0 and CIE0 < CDE0 then class "CIE off" 
(D4)  If R0 >= CDE0 and L0 >= CDE0 and CIE0 > CDE0 then class "CIE on" 
 
The developed method thus identifies either the ligand or the receptor as the limiting fac-
tor for pathway activation, which exactly reproduces the requirements determined by 
Schmidt-Glenewinkel et al. for steady state class I associated with no or low CIE-
internalization [85] (Tab. 6.6). 
For a moderate activation of the CIE-pathway, both the ligand and receptor initial values 
have to exceed the number of CDE-adaptors (condition (S2), Table 6.6), which is re-
flected in the top two decision nodes combined with each other and more explicitly stated 
by the first two terms of rule (D4) for pathway activation (“R0 >= CDE0” and “L0 >= 
CDE0”, Tab.6.7). 
However, for a full activation (condition (S3), Table 6.6) leading the system towards 
steady state class II, ligand and receptor have to exceed the sum of CDE- and CIE-
adaptors according to Schmidt-Glenewinkel et al [85]. This condition is not obvious from 
the decision tree and the corresponding rule set. 
Therefore the influence of component start values on pathway activation was explored by 
simulation and visual inspection of component levels of receptor internalized via CIE and 
CDE at steady state. Simulations were performed for initial values in the order of magni-
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tude of original values [85] with fixed start values for ligand and receptor (L0 = R0 = 1.5) 
and varying start values of adaptor components (CIE0 and CDE0 ∈  [0, 2.5]). 
Simulation results for L:R:CIE- and L:R:CDE- levels at steady state are illustrated ac-
cording to the conditions previously identified (Tab.6.6, [85]) in Fig. 6.10 and according 
to the decision tree results in Fig. 6.11. 
The steady state levels of receptors internalized via CIE and classified as ‘pathway on’ 
(moderate or full) depicted in Fig.6.10 in yellow and green show a large overlap with the 
decision tree result of Fig. 6.11 (‘pathway on’ coloured in green). However, the decision 
tree performs a binary classification (‘pathway on’ or ‘pathway off’ depicted in green and 
red respectively (Fig. 6.11) instead of a three-fold categorization (full, moderate and off) 
and is more restrictive for CIE0 and CDE0 ∈  [0, 1.5] i.e. for initial adaptor values lower 
than ligand and receptor concentration.  
Hence the decision tree categorizes the subspace for CIE0+CDE0 < L0 (= R0 = 1.5) as not 
activated (Fig. 6.11) other than the analytical solution (Tab.6.6), which identifies this sub-
space as ‘pathway activated’ although at fairly low absolute values of L:R:CIE as well as 
low relative levels compared to L:R:CDE are observed (Fig. 6.10). 
Further, pathway activation according to the decision tree was compared to pathway acti-
vation according to the predefined criterion for classification of parameter sets (step 1 
section 4.2.1). Here, the decision tree is less restrictive than the predefined criterion due 
to simple rules of our approach used as features. Therefore a larger area is assigned to 
‘pathway on’ as result of the decision tree (Fig. 6.11) compared to the result of the prede-
fined criterion (Fig. 6.12, green area). 
The developed method is therefore able to identify the previously published conditions 
leading to an inactive CIE-pathway as well as conditions resulting in a large overlap for 
an active CIE-pathway. Moreover, simulation results show that it is crucial which charac-
teristics are regarded as representing pathway activation. 
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Figure 6.10: Conditions for pathway activation according to steady state analysis 
Amount of receptors internalized via CIE and parameters fulfilling conditions identified by steady state 
analysis of Schmidt-Glenewinkel et al. [85] for full pathway activation in green, for moderate activation in 
yellow and no activation in red. For comparison, the amount of receptors internalized via CDE is plotted in 
blue. Results were observed for t = 200 at steady state. Ligand and receptor initial values set to L0 = R0 = 
1.5. 
 
Figure 6.11: Conditions for pathway activation according to the decision tree  
Amount of receptors internalized via CIE and parameters fulfilling conditions identified by decision tree 
analysis for pathway activation colored in green and, in case, conditions are not fulfilled in red. 
For comparison, the amount of receptors internalized via CDE is plotted in blue. Results were observed for 
t = 200 at steady state. Ligand and receptor initial values set to L0 = R0 = 1.5. 
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Figure 6.12: Conditions for pathway activation according to predefined criterion 
Amount of receptors internalized via CIE according to predefined criterion for classification of parameter 
sets into class 1 (‘pathway on’) in green and class 0 (‘pathway off’) in red. For comparison, the amount of 
receptors internalized via CDE is plotted in blue. Results were observed for t = 200 at steady state. Ligand 
and receptor initial values set to L0 = R0 = 1.5. 
 
 
6.4.3 Comparing DLE and decision tree approach using a model of 
caspase activation 
The caspase activation model of Aldridge et al. (Fig. 5.3) was used in order to compare 
the developed method to a different approach of multivariate model analysis for signaling 
networks, called Direct Lyapunov exponent (DLE) analysis. 
Direct Lyapunov exponent (DLE) analysis is a multivariate method for local sensitivity 
analysis. Inspection of DLE values enables identification of regions in phase space (the 
set of initial chemical species concentrations) that give rise to different system responses, 
here survival or apoptosis, respectively [4] (Fig. 6.16). The caspase model contains eight 
molecular species including pro-apoptotic procaspase-3, caspase-3, procaspase-8 and cas-
pase-8 and pro-survival factor XIAP as well as three intermediate products (Fig. 5.3). 
Cells were previously categorized as apoptotic if they exhibit a relatively tall and wide 
pulse of active caspase-3 [4]. Figure 6.13 shows examples of caspase-3 trajectories repre-
senting apoptosis and survival. Accordingly, we set the definition for classification of 
parameter sets to the class ‘apoptosis’ (class 1), if their resulting caspase-3 trajectories 
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exhibit a pulse lasting for at least two hours at a level higher or equal to 1.5 ∙ 10+05 mole-
cules per cell and to ‘survival’ (class 0) otherwise. 
 
 
Figure 6.13: Classification criterion for the caspase-3 activation model 
 
Rate constants were set to original values and similar ranges for initial conditions of com-
ponent concentration were used as originally proposed [4]. While initial values for inter-
mediate products (active caspase-3 and any active caspase bound to a pro-caspase or 
XIAP) are generally assumed to be zero in our approach, the presence of active caspase-8 
was necessary in this case to initiate the caspase cascade and hence was set to the same 
range as published by Aldridge et al. [4]. In total 50,000 parameter sets were generated 
for initial concentrations of four components (procaspase-8, active caspase-8, procaspase-
3 and XIAP). From these parameter sets, 3012 (1506 per class) were selected for training 
of the decision tree. Details of the simulation can be found in Appendix B 
The misclassification errors of all sub-trees obtained by the decision tree algorithm sug-
gest a tree containing six leaf nodes as the tree on the best pruning level. 
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However, even decision trees with fewer terminal nodes show good performance as indi-
cated by the decreasing misclassification error (Fig. 6.14). 
 
 
Figure 6.14: Error decline for capsase-3 activation model (Aldridge et al.) 
 
We consider an accuracy of 80% to suffice for identification of conditions for cell fate 
decision. Therefore we here present decision trees with a corresponding misclassification 
of about 20% and more accurate trees in the supplementary information. The full tree is 
shown in Appendix B. 
The top decision node suggested by our analysis identifies the relation of active caspase-8 
and XIAP as the most important feature (Fig. 6.15) which accounts for the reduction of 
the misclassification error to 25.7% (Fig. 6.14). 
The balance between active caspase-8 and XIAP has also been identified by Aldridge et 
al. to influence cell fate: The higher the concentration of active caspase-8, the higher 
XIAP levels are needed to cross the separatrix of large DLE values from death to survival 
[4] (Fig. 6.16). The same notion is reflected in our results by the top decision node con-
taining the relation of active caspase-8 and XIAP (Fig. 6.15) where a XIAP level exceed-
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ing that of active caspase-8 is linked to survival, while caspase-8 concentration higher 
than XIAP is associated with apoptosis.  
The leaf node representing the class “survival” in Fig. 6.15A yields a class probability of 
1.0 and therefore corresponds to a pure subset due to the split of the top decision node.  
                            
Figure 6.15: Decision trees resulting from analysis of the caspase-3 activation model 
Decision trees resulting from analysis of the caspase activation model illustrated in Fig. 6 
for a misclassification error of 25.7% (A) and 17.43% (B). 
 
 
However, caspase-8 exceeding XIAP can still lead to survival in case procaspase-3 con-
centration is lower than XIAP, as indicated by addition of the second decision node (Fig. 
6.15B) leaving 17.43% parameter sets as wrongly classified to cause apoptosis. 
The second decision node in combination with the root node reflects the need for enough 
procaspase-3 as substrate for cleavage by caspase-8 to high levels of active effector cas-
pase-3, which is required for apoptosis.  
Although our method suggests a multivariate result by combinations of decision nodes to 
lead to a decrease of the misclassification error which can be interpreted towards the 
specified system response, the strongest reduction of misclassification is achieved by the 
top node able to classify 74.3% of the generated parameter sets correctly. Our method 
thus selects as most important feature for classification the relation of XIAP and caspase-
8, which agrees with the result of Aldridge et al. for analysis of the caspase-3 activation 
model. Compared to the DLE, our method does not require visualization and exploration 
of phase space. Instead it directly suggests simple rules yielding the most important mole-
cule relations on top of the decision tree. 
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Figure 6.16: Visualization of DLE values (from Aldridge et al. [4]) 
 
 
6.4.4 Predictions for FAS-mediated apoptosis  
The decision tree approach for model analysis was applied to the apoptosis model of 
Neumann et al. [73] illustrated in Fig. 5.4. Experiments showed, that a ligand concentra-
tion of 250 ng/ml results in a cell death rate of more than 70% [73]. For a ligand concen-
tration of 250 ng/ml, the trajectory of active caspase-3 (C3*) was inspected which reaches 
a maximum concentration of 0.05 nM with an initial value for procaspase-3 (C3) of 1.5 
nM leading to a ratio of max(C3*)/C3y0 = 0.03. Therefore, class definition was set in col-
laboration with L. Neumann to: 
 
class 1 (apoptosis), if max(C3*)/C3(t0) > 0.02      
class 0 (survival) otherwise 
 
The decision tree pruned to the best level requires four decision nodes and five leaf nodes 
yielding a misclassification cost of 0.048 (Fig. 6.17). Since we consider a misclassifica-
tion error of 0.2 as sufficient to give an insight into the interactions predicted to lead to 
cell death, corresponding subtrees will be presented. 
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The top decision node (Fig. 6.18A) resulting from our model analysis approach suggests 
the balance of two DED-containing species, procaspase-8 and c-FLIPS as the most impor-
tant relation accounting for a reduction of the misclassification error to 0.28. 
The decision node on the second level further decreases the misclassification to 0.15 and 
suggests higher c-FLIPL compared to the receptor-FADD component to lead to survival, 
given procaspase-8 levels exceeding c-FLIPS (Fig. 6.18B). 
 
 
Figure 6.17: Misclassification error for model analysis of CD95/Fas-model 
 
The top decision node suggesting survival for initial concentrations of c-FLIPS levels 
higher than procaspase-8 thus reflects the notion of competitive binding of c-FLIPS and 
procaspase-8 to the DISC hampering caspase-8 activation. 
The role of c-FLIPL has been discussed to be anti-apoptotic at high concentrations [20] 
[56] or pro-apoptotic at low concentrations [20]. A recent study of Fricker et al. revealed 
experimentally, that not solely the amount of c-FLIPL, but receptor stimulation influences 
the pro- or anti-apoptotic effects of c-FLIPL. [36]. 
The model component representing receptor stimulation in the analysed CD95-model of 
Neumann et al. is the receptor-FADD (RF) component [73]. Hence, the relation of RF 
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and c-FLIPL as the second decision node represents the dependence of receptor stimula-
tion on c-FLIPL for cell death. 
Further, the top two decision nodes combined with each other reflect the finding that, 
over-expression of a short c-FLIP-isoform in combination with over-expression of c-
FLIPL strongly inhibits apoptosis enabling an even higher percentage of cells to survive 
than either of the c-FLIP isoforms alone [36]. Furthermore, DISC components, specifical-
ly c-FLIP isoforms have been previously identified by sensitivity analysis as most in-
fluential components. Hence my method applied to a model of CD95-mediated apoptosis 
agrees with previous experimental and computational findings that DISC components, in 
particular c-FLIP isoforms are influential components with regard to cell death. 
 
A         B 
                 
Figure 6.18: Resulting decision trees for analysis of CD95/Fas - model 
 
6.4.5 Prediction for a comprehensive apoptosis model 
The decision tree approach for model analysis was applied to the comprehensive model of 
Albeck et al. [3] with a class definition based on their observations on delay time (Td) and 
switching time (Ts) for caspase-3 activity using PARP levels as explained in section 5.2. 
Additionally, it was required that at least 50% of PARP has to be cleaved for the classifi-
cation of the system response. Therefore classes for categorizing generated parameter sets 
were set to:  
 
class 1 (apoptosis) if Ts < 30 minutes and 50% PARP is cleaved  
class 0 (survival) otherwise. 
 
We applied our method to EARM v1.0 by generating 100,000 random parameter sets 
within a range of four orders of magnitude centred at original start values for 18 chemical 
species which require non-zero start values (see Appendix B for details). We then choose 
PC8 < FS
s apo
yes no
RF < FL
PC8 < FS
s
apo
yes no
s
yes no
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93,046 parameter sets (46,523 per class), as input for the decision tree algorithm. Mis-
classification error shows an early decline and a good classification performance for less 
than ten nodes (Fig. 6.19). 
 
 
Figure 6.19: Misclassification error for model analysis of EARM v1.0 
 
Again, we are interested in the conditions required for apoptosis instead of building the 
most accurate classifier and have a closer look at all subtrees up to a misclassification 
error of 0.2. 
 
Subtree containing one decision node 
Our approach identifies the relation of XIAP compared to the model component Smacm 
representing mitochondrial Smac as the top node accounting for a misclassification error 
of 0. 309. The top node suggests survival for Smac exceeding XIAP and apoptosis other-
wise (Fig. 6.20A). 
Due to the model structure of EARM v1.0, the component Smacm is not formed without 
pore formation of the mitochondria (component M*). Mitochondrial outer membrane 
permeabilization (MOMP), which has been shown by experiments to be the crucial event 
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for effective apoptosis [3] [2], therefore is an implicit prerequisite for the top decision 
node. 
Smac/DIABLO (Direct IAP Binding Protein With Low pI) is a protein released from the 
mitochondria, which physically interacts with IAPs relieving the inhibitory effect of IAPs 
on caspase-3 and thereby sensitizing cells for apoptosis [92] [31]. It was shown by Ver-
hagen et al. that the ratio of IAP to DIABLO determines whether cells undergo apoptosis 
or not. Smac and XIAP were integrated into EARM v1.0 as direct interaction partners by 
Albeck et al. [3]. The top decision node therefore identifies a pathway interaction inte-
grated into the analyzed comprehensive apoptosis model as well as a relation that has 
been previously shown by experiments to influence cell fate. 
 
                                               
 
           
Figure 6.20: Decision trees resulting from analysis of apoptosis model EARM v1.0 
Decision trees resulting from analysis of apoptosis model EARM v1.0 (Albeck et al. [3], illustrated in Fig. 
5.1) for a misclassification error of 30.85% (A), 24.68% (B), 21.17% (C) and 18.13% (D). 
 
Subtree containing two decision nodes 
The second decision node predicts higher Bid compared to Bcl-2c (denoting Bcl-2 mole-
cules in the cytosol) concentrations to lead to cell death, but Bid levels lower than Bcl-2c 
to be able to save cells from apoptosis when mitochondrial Smac still exceeds XIAP. 
These two decision nodes account for a misclassification of 0.247. Like the top node, the 
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second decision node contains known apoptosis antagonists [94] (Fig. 6.20B). Bid was 
also integrated into the model as a component sequestering cytosolic Bcl2 [13].  
 
Subtree containing three decision nodes 
In case both pro-apoptotic conditions are met, Smacm exceeding XIAP as well as Bid 
exceeding Bcl-2c, concentrations of Bax higher than mitochondrial Bcl-2 are suggested 
by the decision tree to lead to apoptosis and Bax lower than mitochondrial Bcl-2 to lead 
to survival. The third level node contains Bax and Bcl-2 (mitochondrial Bcl-2) and ac-
counts for 0.211 of misclassification rate. 
As for the first and the second node, the third decision node selected by our method sug-
gests relations of molecular species which have been integrated into the model as direct 
interaction partners representing antagonists for cell fate based on previous experimental 
results [74]. 
 
Subtree containing five decision nodes 
The alternative path from root to bottom assuming XIAP levels higher than Smacm con-
centrations combines two decision nodes within one pruning step (XIAP versus procas-
pase-9 and Bid versus Bcl2-c) (Fig. 6.20D). For concentrations of XIAP exceeding both 
Smacm and procaspase-9, cell survival is predicted. For concentrations of XIAP lower 
than procaspase-9, again Bid concentration higher than Bcl-2c levels are connected to 
apoptosis whereas molecule concentrations of Bid lower than Bcl-2c levels are associated 
with survival resulting in a misclassification rate of 0.181. 
Compared to the known antagonists Bid and Bcl-2, the importance of the apoptosis inhi-
bitor XIAP versus pro-apoptotic caspase-9 is less obvious, since these molecules are not 
direct interaction partners of EARM v1.0. However, within the analyzed apoptosis model, 
caspase-9 is involved in formation of the apoptosome followed by caspase-3 activation 
and XIAP is modeled as a direct inhibitor of caspase-3. Hence, the decision node contain-
ing the relation of XIAP and procaspase-9 identifies the balance between caspase-3 acti-
vation and a caspase-3 inhibition as an important relation for apoptosis. 
For XIAP exceeding both Smacm and procaspase-9, the decision tree suggests that Bid 
concentrations exceeding Bcl-2c can overcome XIAP inhibition and lead to apoptosis by 
Bid sequestering cytosolic Bcl2. In case active caspase-8 is present, Bid can be cleaved to 
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tBid and further enhance the activity of the intrinsic pathway for a quick and effective cell 
death. 
Our method applied to the comprehensive apoptosis model EARM v1.0 thus identifies 
component relations as decision nodes containing molecules acting as antagonists of 
death or survival. 
Decision nodes suggested by our method not only represent crucial interactions within the 
mathematical model, but also important molecule ratios for cell fate identified by experi-
ments in previous studies as will be explained in the following section. 
 
6.4.6 Predictions proved in experimental data and literature 
The relations suggested by the decision tree depicted in Fig. 6.20 were checked computa-
tionally in the OralTongue gene expression data set. Analysis of this data set resulted in 
the lowest p-value for the globaltest (Tab. 6.2) and hence was expected to most likely 
reflect decision tree relations. However, relations of the decision tree nodes found to be 
for anti-apoptotic components more abundant in normal samples than pro-apoptotic com-
ponents and pro-apoptotic components more abundant in tumor samples than anti-
apoptotic components (Fig. 6.21). 
Smac was not measured on the microarray used to generate the OralTongue data set, 
therefore the focus in this section is on predictions with regard to Bcl2-family members.  
Since gene expression data does not reflect in which cellular compartment molecules re-
side, hence model components Bcl2c and Bcl2 were both compared to gene expression 
levels of probes corresponding to Bcl2. 
The relation “Bid < Bcl2” chosen as second and fifth decision node (Fig. 6.20B, Fig. 
6.20D) was found in 78% of the normal samples and in 19% of the tumor samples (Fig. 
6.21) for one pair of probes. Hence anti-apoptotic Bcl2 exceeds pro-apoptotic Bid more 
frequently in normal samples compared to tumor cells. Another pair of probes corre-
sponding to the relation “Bid < Bcl2” shows relative frequencies of 15% and 3% for nor-
mal and tumor respectively. Here, most samples showed higher values for pro-apoptotic 
Bid compared to anti-apoptotic Bcl2 in both, normal and tumor. However the relation Bid 
< Bcl2 associated with apoptosis resistance  still was five times more frequently found in 
normal than in tumor tissue (Fig. 6.21). 
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Bax and Bcl2 are represented by several pairs of probe sets, where all relations “Bax < 
Bcl2” are more often found in normal than in tumor samples. Here again anti-apoptotic 
Bcl2-levels are higher than pro-apoptotic Bax in normal samples (Fig. 6.21). 
A further check within other gene expression data sets was conducted by comparing the 
decision nodes of the tree in Fig. 6.20 with gene expression relations listed in Table 6.4 
and in Appendix A.  
Again, Bcl2 was higher expressed than pro-apoptotic family members in normal, whereas 
Bax and Bid exceeded Bcl2 expression in tumor samples. 
These findings seem counterintuitive, since due to the gene expression data, gene expres-
sion levels of pro-apoptotic factors are up-regulated compared to their ant-apoptotic an-
tagonists in tumor cells. According to these results, tumor cells seem to be more prone to 
apoptosis than normal cells. Hence the predicted relations could not be confirmed as re-
sponsible to apoptosis resistance for the given data sets. 
In spite of these findings on the gene expression level, previous experimental findings 
agree with decision tree relations to control cell fate decisions. For that however, mole-
cule relations controlling death and survival were tested on the protein level. 
With regard to the top decision node relation in Fig. 6.17, it was shown by Verhagen et al. 
that the ratio of IAP to DIABLO could determine whether cells undergo apoptosis or not 
[92]. Further, Bid has been shown to sequester cytosolic Bcl2 [13]. And in case active 
caspase-8 is present, Bid can be cleaved to tBid in order to enhance pro-apoptotic signal-
ing by activation of the intrinsic pathway for a quick and effective cell death. 
Also, Bax and Bcl-2 (mitochondrial Bcl-2) were previously identified by Oltvai et al. [74] 
to interact and influence cell death. 
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Figure 6.21: Relative frequencies of predicted relations in tumor and normal 
Each bar represents a relation of gene expression values of the OralTongue data set. Probes corresponding 
to each bar are listed in Tab. 6.8. The percentage of normal and the percentage of tumor samples that 
showed the corresponding relation of expression levels are colored in green and red respectively. Bars 
marked with an asterix (*) correspond to the relation Bid < Bcl2. All other bars illustrate relative frequen-
cies corresponding to Bax < Bcl2. The figure shows that anti-apoptotic Bcl2 exceeds pro-apoptotic Bcl2-
family members (Bax and Bid) in normal cells compared to tumor cells. The reverse notion is found for 
tumor cells. Here pro-apoptotic Bax and Bid exceed Bcl2. Missing red areas (bars 6, 15, 16 and 18) indi-
cate, that all tumor samples showed the relation Bcl2 < Bax. Probe pairs that do not show any differences 
between normal and tumor were not considered. 
 
Table 6.8: Probes corresponding bars illustrated in Fig. 6.21 
Each bar illustrated in Fig. 6.21 represents a comparison of gene expression values. These  
values correspond to a relation of certain apoptosis pathway components and are measured 
as two probe as listed below. 
Bar Relation Probes  Bar Relation Probes 
1 BAX < BCL2 1997_s_at < 2038_g_at  10 BAX < BCL2 1998_i_at < 1910_s_at 
2 BID < BCL2 32725_at < 2060_at  11 BAX < BCL2 1998_i_at < 2038_g_at 
3 BAX < BCL2 1997_s_at < 1910_s_at  12 BAX < BCL2 2066_at < 1910_s_at 
4 BAX < BCL2 2067_f_at < 2060_at  13 BAX < BCL2 2066_at < 2038_g_at 
5 BAX < BCL2 2065_s_at < 1847_s_at  14 BID < BCL2 32725_at < 1847_s_at 
6 BAX < BCL2 1997_s_at < 2060_at  15 BAX < BCL2 2065_s_at < 1909_at 
7 BAX < BCL2 2067_f_at < 1847_s_at  16 BAX < BCL2 2067_f_at < 1909_at 
8 BAX < BCL2 2065_s_at < 2060_at  17 BAX < BCL2 2067_f_at < 1910_s_at 
9 BAX < BCL2 1997_s_at < 1847_s_at  18 BAX < BCL2 1997_s_at < 1909_at 
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7 Discussion and Outlook 
Studies that investigate disease and clinical phenotypes generally use statistical methods 
on high-throughput data to identify genes or groups of genes associated with the disease 
state. Researchers interested in cellular phenotypes or processes however, investigate 
molecule interaction and dynamics in order to uncover mechanism. These two types of 
study approaches have so far unconnectedly coexisted.  
This thesis combined statistical analyses and mechanistic analyses in a new way. 
The motivation for the presented work was to understand interactions and mechanisms 
involved in apoptosis in the context of cancer development. Therefore, analysis of gene 
expression data from clinical phenotypes was combined with simulation of apoptosis and 
analysis of the resulting system response. To this end two approaches were followed, 
which includes the development of two scaling methods and a novel method for model 
analysis of a system of differential equations. 
 
7.1 Scaling start values according to gene expression data 
The first approach investigated if gene expression data reflects pathway disruptions and 
consequently results in a system response different for values scaled according to tumor 
and normal samples respectively. Two methods for scaling initial values of model com-
ponents were developed and start values were scaled according to eight different data 
sets, which did not yield clear differences with regard to the switching time TS of PARP 
time courses, a characteristic associated with apoptosis.  
Scaling of initial values of the apoptosis model using the fold change of gene expression 
values did not yield differences with regard to TS. Although start values after scaling were 
much larger or lower than original values, this only had an effect on the delay time Td. 
The switching time, however, remained nearly unchanged for all tested data sets. The fold 
change-scaled start values result from averaging several samples per class. Hence, effects 
on the gene expression level could have been diminished for obtaining scaling factors. 
Therefore a second scaling method was developed. 
In order to avoid effects from averaging, scaling per sample was applied to original val-
ues. Here, for each sample a separate system response could be observed, which similar 
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did not show remarkable differences between tumor and normal samples with respect to 
system output of apoptosis. 
These results can be explained by different hypothesis. Molecule levels represented by 
microarray data may not reflect protein concentrations. Apoptosis is a process based on 
cell signaling on a time scale of minutes or hours, gene transcription sometimes proceeds 
on a slower scale. In this work, gene expression measurements were assumed to be pro-
portional to steady state levels of apoptotic protein components. However several mecha-
nisms might interfere with this correlation [41]. 
Reasons for this could be post-transcriptional regulation or protein degradation, both in-
fluence the amount of functional signaling molecules and thus may eliminate the correla-
tion between mRNA and protein levels. Using protein data ideally obtained by quantifica-
tion of single cells could help to elucidate the effect of different molecule abundances on 
system response, but is currently too challenging to be performed on a genome-wide 
scale. 
Another explanation for the observed results could be that the model of Albeck et al. [3] 
is optimised for HeLa cells and may not perfectly represent apoptosis in cells within their 
natural microenvironment, such as in a tumor. The model would be need to be adapted to 
this situation by exploring time series of protein data from patients and healthy individu-
als to fit parameters according to this system. Again, this is currently far beyond the scope 
of available experimental methods. 
Complementary analysis of gene expression data by ranking molecule relations revealed 
anti-apoptotic Bar (BFAR) to be more abundant in cancer samples than pro-apoptotic 
caspase-8 in the breast cancer data set. In this case an anti-apoptotic component exceeds a 
pro-apoptotic component in tumor samples, which agrees with the assumption that cancer 
cells evade apoptosis due to abundant anti-apoptotic components. Together with the find-
ing of Stegh et al. [88] who showed that BFAR inhibits caspase-8 in the breast cancer cell 
line MCF-7 and further prevents the cleavage of Bid and caspase-3, this suggests that the 
identified molecule relation contributes to apoptosis resistance. 
Previous studies with a focus on signaling pathways have so far emphasized receptor state 
of cells as crucial for progress of breast cancer [43]. The finding based on gene expres-
sion data from cancer patients indicates that the connection between extrinsic and intrin-
sic pathway represented by Bid as well as the core machinery of apoptosis (caspases) 
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might be affected by BFAR and thus are responsible for impaired apoptosis in breast can-
cer. This result was not detectable on the level of fold changes, though, since these were 
close to 1 for all analyzed apoptosis components for this data set. 
Fold changes for all data sets identified most pro-apoptotic components in cancer to be 
up-regulated, and most anti-apoptotic pathway components to be down-regulated com-
pared to normal samples, which is against intuition given common apoptosis resistance in 
cancer. Again, this could be due to incomplete correlation between mRNA and protein 
concentrations, to disruption of apoptosis by mechanisms that are not reflected by expres-
sion changes (such as inactivating mutations), or to neglect of our models of further 
pathways that may cross-talk to apoptosis. 
Subpathways in terms of extrinsic and intrinsic components were inspected and in case 
corresponding expression levels were up- or down-regulated, subpathways were consid-
ered as turned on or off, respectively. This analysis revealed the intrinsic pathway to be 
turned on in prostate cancer as well as in the HeadAndNeck data set, whereas the extrin-
sic pathway was turned on in CML. 
Prostate cancer cells can be effectively killed via the intrinsic pathway by indole-3 [72]. 
This might be due to up-regulation of the intrinsic pathway in prostate cancer cells. A 
suggestion for further investigation is to test indole-3 also for head and neck cancer. In 
the case of CML the extrinsic pathway could be used as selective mechanism similar to 
the example of prostate cancer.  
Although scaling of start values did not lead to a different system response for tumor and 
normal samples, the approach “from data to model” including complementary gene ex-
pression data did give an insight into parts of the apoptosis pathway, which should be 
investigated in more detail on the protein level. For breast cancer, prostate cancer as well 
as head and neck cancer, specific points of potential pathway intervention were sug-
gested. Here, data from patients and not from cell lines were used, which increases the 
chances to find important apoptosis traits in vivo. This might help to develop specific 
therapies according to the type of cancer, or even for an individual patient. 
 
7.2 Model analysis to generate hypotheses 
A novel method for model analysis was developed in the course of this thesis. It suggests 
conditions for a certain system response given a particular mathematical model of a 
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pathway, and a definition of the system response. Here, the model is assumed to be a pri-
ori correct. Molecule relations instead of absolute values are considered as crucial condi-
tions for pathway activation. The latter is based on the notion that threshold values for 
molecule abundances exist. In order to find parameter relations which lead to pathway 
activation, the parameter space for initial concentrations is scanned by randomly generat-
ing parameter sets. Sampled parameter sets are used for pathway simulation and classified 
as pathway-activating or non-activating sets based on a predefined criterion. These para-
meter sets together with the corresponding, binary system response are then subjected to a 
decision tree algorithm which learns parameter relations and results by inferring rule sets 
dissecting the parameter sets into the pathway activation classes. 
Learning of ratios instead of concentrations instead of using each absolute concentration 
has the consequence that the method subdivides the input space by diagonal cuts instead 
of cuts orthogonal to variable axis (Fig. 3.1). Using probability distributions defined on 
the entire input space, this method is global and multivariate. It further yields intuitively 
understandable results and is adaptable to the particular research question. The dynamic 
analysis is crucial to analyze pathway activation, since it has been shown that steady 
states are not necessary for pathway activation e.g. for apoptosis [4]. 
 
7.2.1 Decision Trees for model analysis compared to alternative 
methods 
My method for multivariate model analysis was applied to two models for technical vali-
dation. I compared the results to steady state analysis and calculation of DLEs, two alter-
native approaches for model analysis. My method was able to find previously identified 
conditions. 
The first case was a model for EGFR internalization. Here, the decision tree method iden-
tifies component relations as required for inactivation and activation of the CIE-pathway, 
which have previously been derived analytically to be responsible for an ultrasensitive 
sorting mechanism (Schmidt-Glenewinkel et al. [85]). However, comparison of methods 
showed that it is crucial which criterion is chosen as an indicator for pathway activation. 
In the case of the EGFR-model, previously identified conditions by Schmidt-Glenewinkel 
et al. for a steady state associated with full pathway activation do not consider the result-
ing levels of the internalized receptors. Hence steady state analysis allows very low levels 
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of internalized receptors to be associated with full pathway activation. Instead, the deci-
sion tree method does consider levels of internalized receptors. Moreover, conditions for 
activation suggested by the decision tree match well with conditions of input region ac-
cording to the predefined criterion for parameter classification. It thus better conforms to 
the initial, pre-defined condition for pathway activation than the analytical solution. The 
decision tree method yields simplified results by clear diagonal separations of the input 
space. Non-linear relations of components to influence pathway activation cannot be cap-
tured. This seems like a drawback, but instead increases the interpretability of the result-
ing decision tree containing molecule relations within decision nodes. 
By using a different machine learning algorithm for analyzing generated parameter sets 
and its association with a system response, more complex interrelations could be identi-
fied, yet the intuitive representation would be lost. In a similar way as accuracy is traded 
for simplicity to get small decision trees, here we trade accuracy of fitting a predefined 
criterion for simplicity to get an easy to interpret representation of molecule conditions 
controlling pathway activation. 
In a second use case, the decision tree approach was applied to the caspase activation 
model of Aldridge et al. [4] to compare the developed method to a different approach of 
multivariate analysis. The resulting decision tree identified as the top node the balance of 
active caspase-8 and XIAP to be important for cell fate as previously reported by Al-
dridge et al. [4]. Although our method suggests a multivariate result by combinations of 
decision nodes to lead to a decrease of the misclassification error, the strongest reduction 
to a misclassification of 0.26 is achieved by the top node alone. 
Compared to the DLE approach originally used by Aldridge et al. [4], our method is 
faster and does not require visualization and exploration of phase space. Instead it directly 
suggests simple rules yielding the most important molecule relations on top of the deci-
sion tree. 
 
7.2.2 Analysis of apoptosis models by decision tree method 
Two biologically relevant models of apoptosis were analysed which resulted in protein 
relations previously reported to highly influence death and survival. First, the developed 
method for model analysis was applied to the CD95/Fas-induced apoptosis model of 
Neumann et al. [73]. I demonstrated that the method can predict biologically relevant and 
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experimentally proven relations to be important for cell death and yields a strategy to 
trigger cell death suggesting the relation of the Fas ligand to FlipL as crucial. 
DISC-proteins, in particular Flip isoforms have been identified previously both by sensi-
tivity analysis and experiments to be the most influential components of CD95/Fas in-
duced apoptosis [73]. Sensitivity analysis however identifies only single proteins as influ-
ential. Decision trees using relations as features instead suggest for the CD95/Fas-model 
interrelations of DISC components, which comply with recent experimental findings of 
Fricker et al. for receptor stimulation and over-expression of a short in combination with 
a long c-FLIP-isoform to influence apoptosis [36]. 
In the case of the comprehensive apoptosis model of Albeck et al. [3] the decision tree 
method confirms the role of already known antagonists and in addition reveals strategies 
to trigger cell death of indirectly interacting components. Experimental results from lit-
erature agree with the identified direct antagonists. Experiments of Verhagen et al. 
showed that the ratio of IAP to DIABLO could determine whether cells undergo apopto-
sis or not [92]. Further, Bid and Bcl2, contained in the second decision node have been 
shown to interact [13], where Bid is a known mediator between the intrinsic and extrinsic 
pathway. Also, Bax and mitochondrial Bcl-2 have been previously identified by Oltvai et 
al. [74] to interact and influence cell death which is suggested by another decision node. 
How the balance of procaspase-9 and XIAP influence cell fate remains to be proven expe-
rimentally. XIAP is considered to be a strong caspase-3. The prediction, that procaspase-9 
levels exceeding XIAP in combination with Bax exceeding Bcl-2 will lead to apoptosis 
implies, that XIAP inhibition can be overcome. Activation of caspase-9 relies on MOMP 
followed by apoptosome formation. Bax is considered to be responsible for mitochondrial 
pore formation. The decision tree therefore identifies a feedback relation which includes 
components that do not directly interact, but nevertheless depend on each other for effec-
tive cell death. It would be therefore interesting to experimentally test, if the suggested 
molecule relations could overcome XIAP inhibition. 
 
7.2.3 From model to data: Conclusion and perspectives 
The second approach of in silico identification of a set of molecule relations crucial for a 
defined system response has been shown to identify important conditions for pathway 
activation. Here the simplicity of resulting decision tree using molecule relations as split-
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ting criteria enables us to interpret system behaviour for its underlying mechanisms in 
terms of rule sets. 
A more complex method for model analysis would be able to capture more complex ef-
fects. However, it would be more difficult to interpret the input/output behaviour of a 
system. 
Further improvements could be done by introducing a fuzzy region for component abun-
dances as threshold. Since the parameters are highly unlikely to take the same values if 
randomly drawn from uniform distributions covering four orders of magnitude, the cate-
gorization of relations (step 3 within the method explanation in section 4.2.1) comes 
down to a binarization. In case crisp threshold values are biologically unlikely or uncer-
tain, a fuzzy region could be introduced for similar values. 
Furthermore, a different probability density e.g. a Gaussian distribution, could be used for 
drawing parameter values. This would turn the approach into a truly global method and 
additionally could reflect certainty or uncertainty of parameter regions. Hence model 
analysis could be connected to another idea in systems biology: parameter uncertainly. 
One might argue that the predicted interrelations had already been integrated into the 
model by previous knowledge from literature and therefore the method would not yield 
new insights. However, assuming the model interactions to be correct does not necessar-
ily imply a higher probability for certain molecule pairs to be chosen as crucial for a cer-
tain system response. The generation of parameters drawn from a uniform distribution 
and selection of equal numbers for activation classes accounts for equal chances for all 
relation to be selected in a decision node. To argue, that analysis of a model which in-
cludes known direct interactions would not yield new insights toward reaching a certain 
outcome implies that the creator of the model designed the model already towards a cer-
tain system response.  
Instead, model design integrates current knowledge of model interactions, which the deci-
sion tree approach correctly re-identified as important for this cellular process. 
The method can of course only identify components integrated into the model, but is not 
restricted to components involved in the same reaction, as shown by the identified rela-
tion of XIAP and procaspase-9 for the comprehensive apoptosis model. 
Changing the model structure would further challenge current knowledge and might lead 
to different molecule relations identified as important for apoptosis e.g. leaving out the 
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caspase-6 feedback loop. The resulting decision tree predictions could be tested experi-
mentally and in that way contribute to the inherent cycle of system biology: Experiment – 
Model - Prediction - Experiment. 
 
7.3 Outlook 
This thesis aimed at explaining cellular mechanism in a systemic fashion with regard to 
clinical phenotypes of cancer. Under the assumptions that molecule abundances are im-
portant for signal transduction, that measurement of protein levels of single tumor and 
normal cells can be obtained and a correct mathematical model of the pathway of interest 
is available, the combination of the two developed approaches can foster further research 
in the field of cancer systems biology:  
The first approach can identify perturbations in a pathway associated with a disease and 
hence yields characteristics which can be used for selectively kill malignant cells leaving 
normal cells alive. Complementary to that, the second approach identifies an effective 
strategy to either activate or inactivate the pathway of interest. 
Both approaches in combination enable to identify a selective and effective strategy for 
targeted therapy which further can contribute to research in the field of personalized 
medicine. 
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8 Appendix  
This part of the thesis contains additional information, results for every used data set and 
specifications of every analyzed mathematical model. 
Appendix A shows system responses according to all given data sets. Fig. 8.1 shows 
PARP-trajectories resulting from FC-scaled start values. Fig. 8.2 shows PARP-
trajectories resulting from start values scaled per sample. Table 8.1 shows the pair-wise 
relations of expression levels for the data set that did not show a significant p-value re-
sulting from a globaltest. 
Appendix B contains details for model simulation. The developed method for model 
analysis requires generation of random parameters for initial values. A uniform distribu-
tion was assumed for all sampled parameters in ranges as specified in Tabs. 8.2, 8.3, 8.4, 
8.5. Sections 8.3, 8.4, 8.5 and 8.6 contain specifications of mathematical models, rate 
constants and time steps for simulation in Matlab. In section 8.7, trees at the best pruning 
level as result of the developed decision tree method are illustrated. 
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8.1 Appendix A 
 
 
 
    
Figure 8.1: PARP-trajectories resulting from FC-scaling 
For the data sets A: OralTongue, B: Breast, C: Lung, D: ProstateSingh, E: ProstateErnst, F: CML, G: 
HeadAndNeck, H: Microdissected 
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Figure 8.2: PARP-trajectories resulting from per sample-scaling 
For the data sets A: OralTongue, B: Breast, C: Lung, D: ProstateSingh, E: ProstateErnst, F: CML, G: 
HeadAndNeck, H: Microdissected 
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Table 8.1: Pair-wise relations of apoptosis components in gene expression data 
Orange background: Relation more often found in tumor, light green background: Relation more often 
found in normal, Red font: A pro-apoptotic component, Dark green font: A pro-survival/anti-apoptotic 
component. Same gene symbols within one relation refer to different probe set IDs of the microarray. 
Pos. ProstateErnst CML HeadAndNeck Microdissected 
1 CFLAR < BCL2 CFLAR < CFLAR BAX < CASP9 CFLAR < CFLAR 
2 CFLAR < BAX CASP8 < BCL2 CASP3 < CASP9 CASP3 < BCL2 
3 CFLAR < BAX CASP8 < BCL2 BAX < BAX CASP6 < BCL2 
4 CASP6 < CASP9 CASP8 < BCL2 BAX < BAX CFLAR < APAF1 
5 BCL2 < BAX BCL2 < BAX CASP6 < XIAP CASP6 < BID 
6 CASP8 < CASP6 CFLAR < DIABLO BAX < CASP9 CFLAR < BCL2 
7 CASP8 < BCL2 CASP8 < CASP6 CASP3 < CASP9 CASP8 < BCL2 
8 BID < BAX CASP6 < BCL2 CFLAR < CASP9 CASP6 < CASP6 
9 CASP3 < CASP9 CFLAR < CFLAR BID < BAX BCL2 < BCL2 
10 PARP1 < CYCS CASP6 < BAX BCL2 < BAX CFLAR < APAF1 
11 BCL2 < BAX BCL2 < BCL2 BCL2 < BAX CASP6 < BAX 
12 CFLAR < CASP3 TNFSF10 < CASP6 CFLAR < PARP1 APAF1 < APAF1 
13 BID < CASP9 CFLAR < CASP8 CFLAR < BCL2 BID < BCL2 
14 BAX < CASP9 CFLAR < CASP8 CFLAR < CASP3 CFLAR < BAX 
15 BAX < CASP9 CFLAR < BAX CASP3 < BCL2 BCL2 < CASP9 
16 PARP1 < PARP1 CFLAR < CFLAR PARP1 < BCL2 CFLAR < BCL2 
17 CASP8 < BCL2 BCL2 < BCL2 BID < BCL2 CFLAR < CFLAR 
18 CASP3 < CASP6 CFLAR < DIABLO BCL2 < BAX TNFSF10 < BCL2 
19 CASP6 < APAF1 BCL2 < BAX BCL2 < BAX CFLAR < CASP6 
20 BCL2 < BAX BCL2 < BCL2 CFLAR < CASP9 CFLAR < BCL2 
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8.2 Appendix B 
 
Table 8.2: Simulation details for the decision tree method (EGFR-model) 
For the EGFR-model 10,000 parameter sets were generated out of which 1808 (904 per class) were chosen 
as input to the decision tree algorithm. 
Variable State 
Description 
Original 
IC 
Range 
(Min) 
Range 
(Max) 
x1 [EGF] Ligand 1.5 0.1 10 
x2 [EGFR] Receptor 1.5 0.1 10 
x3 [L:EGFR] Ligand-Receptor Complex 0 0 0 
x4 [CIE] CIE-adaptors 2.5 0.1 10 
x5 [L:R:CIE] 
Ligand activated receptor interna-
lized via CIE 0 0 0 
x6 [CDE] CDE-adaptors 2.5 0.1 10 
x7 [L:R:CDE] 
Ligand activated receptor interna-
lized via CDE 0 0 0 
 
Table 8.3: Simulation details for the decision tree method (Caspase-model) 
For the Caspase-model 50,000 parameter sets were generated out of which 3012 (1506 per class) were cho-
sen as input to the decision tree algorithm.  
Variable Symbol Description 
Original IC 
(Min, Max) 
Range (Min) Range (Max) 
x1 [PC8] Procaspase-8 100, 3.5×105 0 3.5×105 
x2 [C8] Active caspase-8 100, 1.0×105 0 3.5×105 
x3 [PC3] Procaspase-3 100, 3.5×105 0 3.5×105 
x4 [C3] Active caspase-3 100, 1.0×105 0 0 
x5 [PC8:C3] 
Procaspase-8 bound to active 
caspase-3 
100, 2.5×104 0 0 
x6 [C8:PC3] 
Active caspase-8 bound to 
procaspase-3 
100, 2.5×104 0 0 
x7 [XIAP] 
XIAP (X-linked inhibitor of 
apoptosis) 
100, 1.0×105 0 3.5e+05 
x8 [C3:XIAP] 
Active caspase-3 bound to 
XIAP 
100, 2.5×104 0 0 
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Table 8.4: Simulation details for the decision tree method (CD95/Fas-model) 
For the CD95/Fas-model 100,000 parameter sets were generated out of which 6848 (3424 per class) were 
chosen as input to the decision tree algorithm. 
Variable Symbol Description Original IC 
Range 
(Min) 
Range 
(Max) 
x1 [L] Anti-CD95 ligand 3.1322×102 3.1322 3.1322×104 
x2 [RF] Receptor-FADD Component 91266×101 91266×10-1 91266×103 
x3 [CD95L:RF] 
Ligand bound to receptor-FADD com-
ponent 0 0 0 
x4 [PC8] Procaspase-8 6.4477×101 6.4477×10-1 6.4477×103 
x5 [CD95L:RF:C8] 
Procaspase-8 bound to ligand-
receptor-FADD component 0 0 0 
x6 [FL] Flip long 7.3986 7.3986×10-1 7.3986×103 
x7 [L:RF:FL] Flip long bound to L:RF- component 0 0 0 
x8 [FS] Flip short 5.0839 5.0839×10-1 5.0839×103 
x9 [L:RF:FS] Flip short bound to L:RF - component 0 0 0 
x10 [p43/p41] 
Intermediate product of caspase-8 
activation 0 0 0 
x11 [p43-FLIP] 
Product from cleavage of Flip long 
and procaspase-8 at the DISC  0 0 0 
x12 [L:RF:C8:FS] Complex of L, RF, C8 and FS 0 0 0 
x13 [L:RF:FL:FL] 
Flip long bound to L:RF:FL - compo-
nent 0 0 0 
x14 [L:RF:FL:FS] Complex of L, RF, FL and FS 0 0 0 
x15 [L:RF:FS:FS] Complex of L, RF, FS and FS 0 0 0 
x16 [C8] Active caspase-8 0 0 0 
x17 [PC3] Procaspase-3 1.4434 1.4434×10-1 1.4434×10-3 
x18 [C3] Active caspase-8 0     
x19 [IKK] IκB Kinase 5.7728 5.7728×10-1 5.7728×10-3 
x20 
[p43-
FLIP:IKK*] Complex of p43-FLIP and IKK* 0     
x21 [NF-kB:IkB] Complex of NF-κB and IκB 0 0 0 
x22 [NF-kB:IkB:P] 
Complex of NF-κB and phosphory-
lated IκB 0 0 0 
x23 [NF-kB*] Active NF-κB  0 0 0 
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Table 8.5: Simulation details for the decision tree method (EARM v1.0-model) 
For the EARM v1.0-model 100,000 parameter sets were generated out of which 93046 (46523 per class) 
were chosen as input to the decision tree algorithm. 
Variable Symbol Description 
Original 
IC 
Range 
(Min) 
Range 
(Max) 
x1 [L] death ligand 3 × 103 3 × 101 3 × 105 
x2 [R] inactive receptor complex 2 × 102 2 2 × 104 
x3 [L:R] ligand-receptor complex 0 0 0 
x4 [R*] active receptor complex 0 0 0 
x5 [flip] 
binds to active receptor acting as 
inhibitor 
1× 102 1 1× 104 
x6 [flip:R*] complex of flip and active receptor 0 0 0 
x7 [C8] procaspase-8 2 × 104 2 × 102 2 × 106 
x8 [C8:R*] 
procaspase-8 bound to active 
receptor 
0 0 0 
x9 [C8*] procaspase-8 and procaspase-10 0 0 0 
x10 [Bar] 
binds to C8* and acts as an inhibi-
tor 1 × 103 1 × 101 1 × 105 
x11 [C8*:Bar] 
complex of active caspase-8/10 
and Bar 
0 0 0 
x12 [C3] procaspase-3 1 × 104 1 × 102 1 × 106 
x13 [C8*:C3] 
complex of active caspase-8/10 
and procaspase-3 
0 0 0 
x14 [C3*] active caspase-3 0 0 0 
x15 [C6] procaspase-6 1 × 104 1 × 102 1 × 106 
x16 [C3*:C6] 
complex of active caspase-3 and 
procaspase-6  0 0 0 
x17 [C6*] active caspase-6 0 0 0 
x18 [C6*:C8] 
complex of active caspase-6 and 
procaspase-8 0 0 0 
x19 [XIAP] 
X-linked inhibitor of apoptosis 
(XIAP) 1 × 105 1 × 103 1 × 107 
x20 [XIAP:C3*] 
complex of XIAP ans active cas-
pase-3 0 0 0 
x21 [PARP] 
DNA damage repair enzyme, here 
represents all substrates of C3* 1 × 106 1 × 104 1 × 108 
 106 
x22 [C3*:PARP] 
complex of active caspase-3 and 
PARP 0 0 0 
x23 [cPARP] cleaved PARP 0 0 0 
x24 [Bid] 
substrate of active caspase-8, 
inactive form of Bid 4 × 104 4 × 102 4 × 106 
x25 [C8*:Bid] 
compex of active caspase-8 and 
Bid 0 0 0 
x26 [tBid] cleaved Bid, active form of Bid 0 0 0 
x27 [Bcl-2c] 
represents the family of anti-
apoptotic Bcl-2 proteins in the 
cellular compartment (CC), it binds 
to tBid and acts as inhibitor 2 × 104 2 × 102 2 × 106 
x28 [tBid:Bcl2c] complex of cleaved Bid and Bcl2c 0 0 0 
x29 [Bax] substrate of tBid, inactive form 1 × 105 1 × 103 1 × 107 
x30 [tBid:Bax] complex of cleaved Bid and Bax 0 0 0 
x31 [Bax*] active form of Bax 0 0 0 
x32 [Bax*m] 
Bax*m in the mitochondrial com-
partment (MC) 0 0 0 
x33 [Bcl2] 
represents all anti-apoptotic Bcl-2 
proteins in the MC 2 × 104 2 × 102 2 × 106 
x34 [Bax*m:Bcl2] complex of Bax*m and Bcl2 0 0 0 
x35 [Bax2] 
represents Bax*m:Bax*m (complex 
of two Bax*m) in the MC 0 0 0 
x36 [Bax2:Bcl2] complex of Bax2 and Bcl2 0 0 0 
x37 [Bax4] 
represents Bax2:Bax2 (complex of 
two Bax2) in the MC 0 0 0 
x38 [Bax4:Bcl2] complex of Bax4 and Bcl2 0 0 0 
x39 [M] 
the number of unoccupied Bcl-2 
proteins in the MC 5 × 105 5 × 103 5 × 107 
x40 [Bax4:M] complex containing Bax4 and M 0 0 0 
x41 [M*] 
the number of pores Bax4 created 
on the outer membrane of the 
mitochondria 0 0 0 
x42 [CyCm] 
cytochrome C inside the mito-
chondria, in MC 5 × 105 5 × 103 5 × 107 
 107 
x43 [M*:CyCm] complex containing M* and CyCm 0 0 0 
x44 [CyCr] 
cytochrome C released from the 
mitochondria, but remaining in MC 0 0 0 
x45 [Smacm] 
Smac/Diablo inside the mitochon-
dria, in MC 1 × 105 1 × 103 1 × 107 
x46 [M*:Smacm] complex containing M* and Smacm 0 0 0 
x47 [Smacr] 
Smac/Diablo released from the 
mitochondria, but remaining in MC 0 0 0 
x48 [CyC] cytochrome c in the CC 0 0 0 
x49 [Apaf] 
Apoptosis Activating Factor (Apaf-
1), substrate of CyC, inactive form 1 × 105 1 × 103 1 × 107 
x50 [Apaf:CyC] 
complex containing Apaf and cy-
tochrome c 0 0 0 
x51 [Apaf*] active form of Apaf-1 0 0 0 
x52 [C9] procaspase-9 1 × 105 1 × 103 1 × 107 
x53 [Apop] 
the apoptosome, which is the 
complex Apaf*:C9 0 0 0 
x54 [Apop:C3] 
complex containing the apopto-
some and procaspase-3 0 0 0 
x55 [Smac] Smac/Diablo in the CC 0 0 0 
x56 [Apop:XIAP] 
complex containing the apopto-
some and XIAP 0 0 0 
x57 [Smac:XIAP] 
complex containing Smac and 
XIAP 0 0 0 
x58 [C3*Ub] 
C3* ubiquinated and targeted for 
degradation, assumed inactive 0 0 0 
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8.3 Specification of the EGFR-model 
 
function responseCurves = runEGFRModel(kMat,yMat,responseVar) 
  time = [0:1:200]; 
  responseCurves =  zeros(length(time),0); 
 
  kf = 1.0; 
  kr = 0.01; 
  kcie = 0.01; 
  kcde = 1.0; 
 
  for (yset = 1:numel(yMat(:,1)) ) 
    
y0=yMat(yset,1);yMat(yset,2);yMat(yset,3);yMat(yset,4);yMat(yset,
5);yMat(yset,6);yMat(yset,7)]; 
     options = odeset('AbsTol', 1e-15,'RelTol', 1e-6); 
     [t,y] = ode15s(@egfrModel,time,y0,options); 
     responseCurve = cat(2,responseCurves,y(:,responseVar));   
% concatenate column-wise;  
     y(:,responseVar)       
  end 
   
  function dydt = egfrModel(t,y)  
    % EGF 
  %  x1 =-kf*EGF*R+kr*R_EGF; 
    x1 =-kf*y(1)*y(2)+kr*y(3); 
   
  % R 
  %  x2 =-kf*EGF*R+kr*R_EGF; 
    x2 =-kf*y(1)*y(2)+kr*y(3); 
   
  % R_EGF 
  %  x3 =+kf*EGF*R-kr*R_EGF-kcie*R_EGF*CIE-kcde*R_EGF*CDE; 
    x3 =+kf*y(1)*y(2)-kr*y(3)-kcie*y(3)*y(4)-kcde*y(3)*y(6); 
   
  % CIE 
  %  x4 =-kcie*R_EGF*CIE; 
    x4 =-kcie*y(3)*y(4); 
   
  % R_CIE 
  %  x5 =+kcie*R_EGF*CIE; 
    x5 =+kcie*y(3)*y(4); 
   
  % CDE 
  %  x6 =-kcde*R_EGF*CDE; 
    x6 =-kcde*y(3)*y(6); 
   
  % R_CDE 
  %  x7 =+kcde*R_EGF*CDE; 
    x7 =+kcde*y(3)*y(6); 
  dydt = [x1;x2;x3;x4;x5;x6;x7]; 
  end 
end 
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8.4 Caspase-model specification 
 
function responseCurves = runCaspaseModel(yMat,responseVar) 
  % time span - ending at 6 hours 
  % time starts at 0 and ends at 21600 seconds, 
  % hence one step corresponds to 43.2866 seconds 
  
  t = linspace(0,6*60*60,500); 
  responseCurves =  zeros(length(t),0); 
 
  for (yset = 1:numel(yMat(:,1)) ) 
    y0 = 
[yMat(yset,1);yMat(yset,2);yMat(yset,3);yMat(yset,4);yMat(yset,5);yMat(y
set,6);yMat(yset,7);yMat(yset,8)]; 
    options = odeset('AbsTol', 1e-15,'RelTol', 1e-6); 
    [t,y] = ode15s(@casp3modelodes,t,y0,options); 
    responseCurves = cat(2,responseCurves,y(:,responseVar));  % concate-
nate column-wise; y(:,responseVar)       
  end 
 
    function dydt = casp3modelodes(t,y) 
 
    %network species 
    c8=y(1);    %casp-8 
    c8a=y(2);   %casp-8* 
    c3=y(3);    %casp-3 
    c3a=y(4);   %casp-3* 
    c8c3a=y(5); %casp-8:casp-3* 
    c8ac3=y(6); %casp-8*:casp-3 
    xiap=y(7);  %XIAP 
    c3ax=y(8);  %casp-3*:XIAP 
 
    %parameters 
    kd2=.008; 
    kd4=1e-3; 
    k1=2.667e-9; 
    kd1=.01; 
    k3=6.8e-8; 
    kd3=.05; 
    k5=7e-5; 
    kd5=1e7/6e11; 
    kd6=1/6000;  
 
    %odes 
    dc8 = -k1*c3a*c8 + kd1*c8c3a; 
    dc8a = kd2*c8c3a -k3*c8a*c3 +kd3*c8ac3 +kd4*c8ac3; 
    dc3 = -k3*c8a*c3 +kd3*c8ac3; 
    dc3a= kd4*c8ac3-k1*c3a*c8+kd1*c8c3a-k5*xiap*c3a+kd5*c3ax +kd2*c8c3a; 
    dc8c3a = -kd2*c8c3a + k1*c3a*c8 - kd1*c8c3a; 
    dc8ac3 = -kd4*c8ac3 +k3*c8a*c3 -kd3*c8ac3; 
    dxiap = -k5*xiap*c3a +kd5*c3ax +kd6*c3ax; 
    dc3ax = k5*xiap*c3a -kd5*c3ax -kd6*c3ax; 
 
    dydt=[dc8;dc8a;dc3;dc3a;dc8c3a;dc8ac3;dxiap;dc3ax]; 
    end 
end 
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8.5 Specification of the CD95/Fas-Model 
 
function responseCurves = runNeumannModel(yMat,responseVar) 
  t = [0:1:360]; 
  responseCurves =  zeros(length(t),0); 
  for (yset = 1:numel(yMat(:,1)) ) 
y0=yMat(yset,1);yMat(yset,2);yMat(yset,3);yMat(yset,4);yMat(yset,5);
yMat(yset,6);yMat(yset,7);yMat(yset,8);yMat(yset,9);yMat(yset,10);yM
at(yset,11);yMat(yset,12);yMat(yset,13);yMat(yset,14);yMat(yset,15);
yMat(yset,16);yMat(yset,17);yMat(yset,18);yMat(yset,19);yMat(yset,20
);yMat(yset,21);yMat(yset,22);yMat(yset,23)]; 
   options = odeset('AbsTol', 1e-15,'RelTol', 1e-6); 
    [t,y] = ode15s(@neumann_model,t,y0,options); 
    responseCurves = cat(2,responseCurves,y(:,responseVar));   
% concatenate column-wise; 
 y(:,responseVar)       
  end 
 
   function dydt = neumann_model(t,y)      
      k1 = 1.0e+00; 
      k2 = 1.28E-04; 
      k3 = 6.69E-01; 
      k4 = 1.0e-05; 
      k5 = 5.95E-04; 
      k6 = 1.0e+00; 
      k7 = 8.88E-01; 
      k8 = 8.04E-04; 
      k9 = 2.25E-03; 
      k10 = 1.21E-01; 
      k11 = 2.89E-02; 
      k12 = 1.50E-01; 
      k13 = 7.20E-04; 
      k14 = 3.59E-01; 
      k15 = 3.68E+00; 
      k16 = 2.23E-02; 
      k17 = 6.42E-03; 
           
    % L 
    %  x1 =-k1*L*RF; 
      x1 =-k1*y(1)*y(2); 
 
    % RF 
    %  x2 =-k1*L*RF; 
      x2 =-k1*y(1)*y(2); 
 
    % L:RF 
    %  x3 =+k1*L*RF-k2*L:RF*C8-k3*L:RF*FL-k4*L:RF*FS; 
      x3 =+k1*y(1)*y(2)-k2*y(3)*y(4)-k3*y(3)*y(6)-k4*y(3)*y(8); 
 
    % C8 
   %x4=-k2*L:RF*C8-k5*L:RF:C8*C8-k5*L:RF:FL*C8-k5*L:RF:FS*C8k10*C8*C3*; 
   x4=-k2*y(3)*y(4)-k5*y(5)*y(4)-k5*y(7)*y(4)k5*y(9)*y(4)k10*y(4)*y(18); 
 
    % L:RF:C8 
    %  x5 =+k2*L:RF*C8-k5*L:RF:C8*C8-k6*L:RF:C8*FL-k7*L:RF:C8*FS; 
      x5 =+k2*y(3)*y(4)-k5*y(5)*y(4)-k6*y(5)*y(6)-k7*y(5)*y(8); 
 
    % FL 
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    %  x6 =-k3*L:RF*FL-k6*L:RF:C8*FL-k6*L:RF:FL*FL-k6*L:RF:FS*FL; 
      x6 =-k3*y(3)*y(6)-k6*y(5)*y(6)-k6*y(7)*y(6)-k6*y(9)*y(6); 
 
    % L:RF:FL 
    %  x7 =+k3*L:RF*FL-k5*L:RF:FL*C8-k6*L:RF:FL*FL-k7*L:RF:FL*FS; 
      x7 =+k3*y(3)*y(6)-k5*y(7)*y(4)-k6*y(7)*y(6)-k7*y(7)*y(8); 
 
    % FS 
    %  x8 =-k4*L:RF*FS-k7*L:RF:C8*FS-k7*L:RF:FL*FS-k7*L:RF:FS*FS; 
      x8 =-k4*y(3)*y(8)-k7*y(5)*y(8)-k7*y(7)*y(8)-k7*y(9)*y(8); 
 
    % L:RF:FS 
    %  x9 =+k4*L:RF*FS-k5*L:RF:FS*C8-k6*L:RF:FS*FL-k7*L:RF:FS*FS; 
      x9 =+k4*y(3)*y(8)-k5*y(9)*y(4)-k6*y(9)*y(6)-k7*y(9)*y(8); 
 
    % p43/p41 
    %x10=+k5*L:RF:C8*C8+k5*L:RF:C8*C8-k8*p43/p41*p43/p41- 
          %k8*p43/p41*p43/p41+k10*C8*C3*; 
      x10=+k5*y(5)*y(4)+k5*y(5)*y(4)-k8*y(10)*y(10) 
k8*y(10)*y(10)+k10*y(4)*y(18); 
 
    % p43-FLIP 
    %  x11 =+k6*L:RF:C8*FL+k5*L:RF:FL*C8-k13*p43-FLIP*IKK; 
      x11 =+k6*y(5)*y(6)+k5*y(7)*y(4)-k13*y(11)*y(19); 
 
    % L:RF:C8:FS 
    %  x12 =+k7*L:RF:C8*FS+k5*L:RF:FS*C8; 
      x12 =+k7*y(5)*y(8)+k5*y(9)*y(4); 
 
    % L:RF:FL:FL 
    %  x13 =+k6*L:RF:FL*FL; 
      x13 =+k6*y(7)*y(6); 
 
    % L:RF:FL:FS 
    %  x14 =+k7*L:RF:FL*FS+k6*L:RF:FS*FL; 
      x14 =+k7*y(7)*y(8)+k6*y(9)*y(6); 
 
    % L:RF:FS:FS 
    %  x15 =+k7*L:RF:FS*FS; 
      x15 =+k7*y(9)*y(8); 
 
    % C8* 
    %  x16 =+k8*p43/p41*p43/p41-k9*C3*C8*+k9*C3*C8* +0 -k11*y(16); 
      x16 =+k8*y(10)*y(10)-k9*y(17)*y(16)+k9*y(17)*y(16) +0 -k11*y(16); 
 
    % C3 
    %  x17 =-k9*C3*C8*; 
      x17 =-k9*y(17)*y(16); 
 
    % C3* 
    %  x18 =+k9*C3*C8*-k10*C8*C3*+k10*C8*C3* +0 -k12*y(18); 
      x18 =+k9*y(17)*y(16)-k10*y(4)*y(18)+k10*y(4)*y(18) +0 -k12*y(18); 
 
    % IKK 
    %  x19 =-k13*p43-FLIP*IKK; 
      x19 =-k13*y(11)*y(19); 
 
    % p43-FLIP:IKK* 
    %  x20 =+k13*p43-FLIP*IKK-k16*y(20); 
      x20 =+k13*y(11)*y(19)-k16*y(20); 
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    % NF-kB:IkB 
    %  x21 =-k14*NF-kB:IkB*p43-FLIP:IKK*; 
      x21 =-k14*y(21)*y(20); 
 
    % NF-kB:IkB:P 
    %  x22 =+k14*NF-kB:IkB*p43-FLIP:IKK*-k15*NF-kB:IkB:P; 
      x22 =+k14*y(21)*y(20)-k15*y(22); 
 
    % NF-kB* 
    %  x23 =+k15*NF-kB:IkB:P +0 -k17*y(23); 
      x23 =+k15*y(22) +0 -k17*y(23); 
    dydt = 
[x1;x2;x3;x4;x5;x6;x7;x8;x9;x10;x11;x12;x13;x14;x15;x16;x17;x18;x19;x20;
x21;x22;x23]; 
   end 
end 
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8.6 Specification of EARM v1.0  
 
function responseCurves = runEARM(yMat,responseVar) 
  % time span - ending at 6 hours 
  % Time settings according to Fig_4B of Albeck et al.     
  tf=6*3600; % seconds 
  samp_freq=tf/60; % accurate to min 
  dt=(tf-0)/samp_freq; 
  tt=0:dt:tf; 
  options=odeset('AbsTol',1E-10,'RelTol',1E-8,'maxstep',dt); 
  responseCurves =  zeros(length(tt),0); 
 
  for (yset = 1:numel(yMat(:,1)) ) 
    y0 = yMat(yset,:)'; 
    [t,y] = ode15s(@rhs,tt,y0,options); 
    responseCurves = cat(2,responseCurves,y(:,responseVar));  % concate-
nate column-wise; y(:,responseVar)       
  end 
 
  function xp=rhs(t,x) 
    % ODE with dimensions  
 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    %                  Rate constants                    % 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
     
    transloc=.01;% rate of translocation between the cytosolic and mito-
chondrial compartments 
    v=.07; % mitochondria compartment volume/cell volume 
     
    % L + pR <--> L:pR --> R* 
    k(1)=4E-7; k_(1)=1E-3; kc(1)=1E-5; 
 
    % flip + DISC <-->  flip:DISC   
    k(2)=1E-6; k_(2)=1E-3; 
 
    % pC8 + DISC <--> DISC:pC8 --> C8 + DISC 
    k(3)=1E-6; k_(3)=1E-3; kc(3)=1; 
 
    % C8 + BAR <--> BAR:C8  
    k(4)=1E-6; k_(4)=1E-3; 
 
    % pC3 + C8 <--> pC3:C8 --> C3 + C8 
    k(5)=1E-7; k_(5)=1E-3; kc(5)=1; 
 
    % pC6 + C3 <--> pC6:C3 --> C6 + C3 
    k(6)=1E-6; k_(6)=1E-3; kc(6)=1; 
 
    % pC8 + C6 <--> pC8:C6 --> C8 + C6 
    k(7)=3E-8; k_(7)=1E-3; kc(7)=1;  
 
    % XIAP + C3 <--> XIAP:C3 --> XIAP + C3_U 
    k(8)=2E-6; k_(8)=1E-3;  kc(8)=.1; 
 
    % PARP + C3 <--> PARP:C3 --> CPARP + C3 
    k(9)=1E-6; k_(9)=1E-2; kc(9)=1; 
 
    % Bid + C8 <--> Bid:C8 --> tBid + C8 
    k(10)=1E-7; k_(10)=1E-3; kc(10)=1; 
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    % tBid + Bcl2c <-->  tBid:Bcl2c   
    k(11)=1E-6; k_(11)=1E-3;  
 
    % Bax + tBid <--> Bax:tBid --> aBax + tBid  
    k(12)=1E-7; k_(12)=1E-3; kc(12)=1; 
 
    % aBax <-->  MBax  
    k(13)=transloc; k_(13)=transloc; 
 
    % MBax + Bcl2 <-->  MBax:Bcl2   
    k(14)=1E-6; k_(14)=1E-3;  
 
    % MBax + MBax <-->  MBax:MBax == Bax2 
    k(15)=1E-6; k_(15)=1E-3; 
 
    % Bax2 + Bcl2 <-->  MBax2:Bcl2   
    k(16)=1E-6; k_(16)=1E-3;  
 
    % Bax2 + Bax2 <-->  Bax2:Bax2 == Bax4 
    k(17)=1E-6; k_(17)=1E-3; 
 
    % Bax4 + Bcl2 <-->  MBax4:Bcl2   
    k(18)=1E-6; k_(18)=1E-3;  
 
    % Bax4 + Mit0 <-->  Bax4:Mito -->  AMito   
    k(19)=1E-6; k_(19)=1E-3; kc(19)=1; 
 
    % AMit0 + mCtoC <-->  AMito:mCytoC --> AMito + ACytoC   
    k(20)=2E-6; k_(20)=1E-3; kc(20)=10;  
 
    % AMit0 + mSMac <-->  AMito:mSmac --> AMito + ASMAC   
    k(21)=2E-6; k_(21)=1E-3; kc(21)=10;  
 
    % ACytoC <-->  cCytoC 
    k(22)=transloc; k_(22)=transloc; 
 
    % Apaf + cCytoC <-->  Apaf:cCytoC   
    k(23)=5E-7; k_(23)=1E-3; kc(23)=1;  
 
    % Apaf:cCytoC + Procasp9 <-->  Apoptosome   
    k(24)=5E-8; k_(24)=1E-3; 
 
    % Apop + pCasp3 <-->  Apop:cCasp3 --> Apop + Casp3   
    k(25)=5E-9; k_(25)=1E-3; kc(25)=1; 
 
    % ASmac <-->  cSmac 
    k(26)=transloc; k_(26)=transloc; 
 
    % Apop + XIAP <-->  Apop:XIAP   
    k(27)=2E-6; k_(27)=1E-3; 
 
    % cSmac + XIAP <-->  cSmac:XIAP   
    k(28)=7E-6; k_(28)=1E-3; 
 
     
    %------------------------------------------------------------- 
 
    xp=double(x); 
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    xp(1) = -k(1)*x(1)*x(2) +k_(1)*x(3) ; % Ligand  
 
    xp(2) = -k(1)*x(1)*x(2) +k_(1)*x(3) ; % R 
 
    xp(3) =  k(1)*x(1)*x(2) -k_(1)*x(3) -kc(1)*x(3) ; % L:R complex 
 
    xp(4) = kc(1)*x(3) +... 
        -k(2)*x(4)*x(5) +k_(2)*x(6) +... 
        -k(3)*x(4)*x(7) +k_(3)*x(8) +kc(3)*x(8); % R* 
 
    xp(5)= -k(2)*x(4)*x(5) +k_(2)*x(6) ; % flip 
 
    xp(6)=  k(2)*x(4)*x(5) -k_(2)*x(6) ; % flip:R* 
 
    xp(7) = -k(3)*x(4)*x(7) +k_(3)*x(8) +... 
        -k(7)*x(7)*x(17) +k_(7)*x(18) ; % pC8  
 
    xp(8) =  k(3)*x(4)*x(7) -k_(3)*x(8) -kc(3)*x(8) ; % R*:pC8 
 
    xp(9) =  kc(3)*x(8) +... 
        -k(4)*x(9)*x(10) +k_(4)*x(11) +... 
        -k(5)*x(9)*x(12) +k_(5)*x(13) +kc(5)*x(13) +... 
        +kc(7)*x(18) +... 
        -k(10)*x(9)*x(24) +k_(10)*x(25) +kc(10)*x(25) ; % C8 
 
    xp(10) = -k(4)*x(9)*x(10) +k_(4)*x(11) ; % Bar 
 
    xp(11) =  k(4)*x(9)*x(10) -k_(4)*x(11) ; % Bar:C8 
 
    xp(12)= -k(5)*x(9)*x(12) +k_(5)*x(13) +... 
        -k(25)*x(12)*x(53) +k_(25)*x(54) ; % pC3 
 
    xp(13)=  k(5)*x(9)*x(12) -k_(5)*x(13) -kc(5)*x(13) ; % C8:pC3 
 
    xp(14)=  kc(5)*x(13) +... 
        -k(6)*x(14)*x(15) +k_(6)*x(16) +kc(6)*x(16) +... 
        -k(8)*x(14)*x(19) +k_(8)*x(20) +... 
        -k(9)*x(14)*x(21) +k_(9)*x(22) +kc(9)*x(22) +... 
        +kc(25)*x(54) ; % C3  
 
    xp(15)= -k(6)*x(14)*x(15) +k_(6)*x(16) ; % pC6 
 
    xp(16)=  k(6)*x(14)*x(15) -k_(6)*x(16) -kc(6)*x(16) ; % C3:pC6 
 
    xp(17)=  kc(6)*x(16) +... 
        -k(7)*x(7)*x(17) +k_(7)*x(18) +kc(7)*x(18) ; % C6 
 
    xp(18)=  k(7)*x(7)*x(17) -k_(7)*x(18) -kc(7)*x(18) ; % C6:pC8 
 
    xp(19)= -k(8)*x(14)*x(19) +k_(8)*x(20) +kc(8)*x(20) +...  
        -k(27)*x(19)*x(53) +k_(27)*x(56) +... 
        -k(28)*x(19)*x(55) +k_(28)*x(57) ; % XIAP 
 
    xp(20)=  k(8)*x(14)*x(19) -k_(8)*x(20) -kc(8)*x(20) ; % XIAP:C3 
 
    xp(21)= -k(9)*x(14)*x(21) +k_(9)*x(22) ; % PARP 
 
    xp(22)=  k(9)*x(14)*x(21) -k_(9)*x(22) -kc(9)*x(22) ; % C3:PARP 
 
    xp(23)= kc(9)*x(22) ; % CPARP 
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    xp(24)= -k(10)*x(9)*x(24) +k_(10)*x(25) ; % Bid 
 
    xp(25)=  k(10)*x(9)*x(24) -k_(10)*x(25) -kc(10)*x(25) ; % C8:Bid 
 
    xp(26)=  kc(10)*x(25) +... 
        -k(11)*x(26)*x(27) +k_(11)*x(28) +... 
        -k(12)*x(26)*x(29) +k_(12)*x(30) + kc(12)*x(30); % tBid 
 
    xp(27)= -k(11)*x(26)*x(27) +k_(11)*x(28) ; % Bcl2c 
 
    xp(28)= +k(11)*x(26)*x(27) -k_(11)*x(28) ; % Bcl2c:tBid 
 
    xp(29)= -k(12)*x(26)*x(29) +k_(12)*x(30) ; % Bax 
 
    xp(30)=  k(12)*x(26)*x(29) -k_(12)*x(30) - kc(12)*x(30) ; % tBid:Bax 
 
    xp(31)=  kc(12)*x(30) +... 
        -k(13)*x(31) + k_(13)*x(32) ; % Bax* 
 
    xp(32)=  k(13)*x(31) - k_(13)*x(32) +... 
        -1/v*k(14)*x(32)*x(33) +k_(14)*x(34) +... 
        -1/v*2*k(15)*x(32)^2 +2*k_(15)*x(35) ; % Baxm 
 
    xp(33)= -1/v*k(14)*x(32)*x(33) +k_(14)*x(34) +... 
        -1/v*k(16)*x(33)*x(35) +k_(16)*x(36) +... 
        -1/v*k(18)*x(33)*x(37) +k_(18)*x(38) ; % Bcl2  
 
    xp(34)=  1/v*k(14)*x(32)*x(33) -k_(14)*x(34) ; % Baxm:Bcl2 
 
    xp(35)=  1/v*k(15)*x(32)^2 -k_(15)*x(35) +... 
        -1/v*k(16)*x(33)*x(35) +k_(16)*x(36) +... 
        -2/v*k(17)*x(35)^2 +2*k_(17)*x(37) ; % Bax2 
 
    xp(36)=  1/v*k(16)*x(33)*x(35) -k_(16)*x(36) ; % Bax2:Bcl2 
 
    xp(37)= 1/v*k(17)*x(35)^2 -k_(17)*x(37)+...  
        -1/v*k(18)*x(33)*x(37) +k_(18)*x(38) +... 
        -1/v*k(19)*x(39)*x(37) +k_(19)*x(40) ; % Bax4  
 
    xp(38)= 1/v*k(18)*x(33)*x(37) -k_(18)*x(38) ; % Bax4:Bcl2 
 
    xp(39)= -1/v*k(19)*x(39)*x(37) +k_(19)*x(40); % M 
 
    xp(40)=  1/v*k(19)*x(39)*x(37) -k_(19)*x(40) -kc(19)*x(40); % Bax4:M 
 
    xp(41)=  kc(19)*x(40) +... 
        -1/v*k(20)*x(41)*x(42) +k_(20)*x(43) +kc(20)*x(43) +... 
        -1/v*k(21)*x(41)*x(45) +k_(21)*x(46) +kc(21)*x(46) ; % M* 
 
    xp(42)= -1/v*k(20)*x(41)*x(42) +k_(20)*x(43) ; % CytoCm 
 
    xp(43)=1/v*k(20)*x(41)*x(42)-k_(20)*x(43)-kc(20)*x(43) ; % M*:CytoCm 
 
    xp(44)=  kc(20)*x(43) +... 
        -k(22)*x(44) +k_(22)*x(48) ; % CytoCr  % CytoC released 
 
    xp(45)= -1/v*k(21)*x(41)*x(45) +k_(21)*x(46) ; % Smacm 
 
    xp(46)= 1/v*k(21)*x(41)*x(45)-k_(21)*x(46)-kc(21)*x(46) ; % M*:Smacm 
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    xp(47)=  kc(21)*x(46) +... 
        -k(26)*x(47) +k_(26)*x(55) ; % Smacr 
 
    xp(48)=  k(22)*x(44) -k_(22)*x(48) +... 
        -k(23)*x(48)*x(49) +k_(23)*x(50) +kc(23)*x(50) ; % CytoC in CC 
 
    xp(49)= -k(23)*x(48)*x(49) +k_(23)*x(50) ; % Apaf 
    xp(50)= k(23)*x(48)*x(49) -k_(23)*x(50) -kc(23)*x(50) ; % Apaf:CytoC 
 
    xp(51)= kc(23)*x(50) +... 
        -k(24)*x(51)*x(52) +k_(24)*x(53); % Apaf* 
 
    xp(52)= -k(24)*x(51)*x(52) +k_(24)*x(53) ; % pC9 
 
    xp(53)=  k(24)*x(51)*x(52) -k_(24)*x(53) +... 
        -k(25)*x(12)*x(53) +k_(25)*x(54) +kc(25)*x(54) +... 
        -k(27)*x(19)*x(53) +k_(27)*x(56) ; % Apop 
 
    xp(54)=  k(25)*x(12)*x(53) -k_(25)*x(54) -kc(25)*x(54) ; % Apop:pC3 
 
    xp(55)=  k(26)*x(47) -k_(26)*x(55) +... 
        -k(28)*x(19)*x(55) +k_(28)*x(57) ; % Smac 
 
    xp(56)=  k(27)*x(19)*x(53) -k_(27)*x(56) ; % Apop:XIAP  
 
    xp(57)=  k(28)*x(19)*x(55) -k_(28)*x(57) ; % Smac:XIap 
 
    xp(58)=kc(8)*x(20); % C3_Ub 
    
dydt=[xp(1);xp(2);xp(3);xp(4);xp(5);xp(6);xp(7);xp(8);xp(9);xp(10);xp(11
);xp(12);xp(13);xp(14);xp(15);xp(16);xp(17);xp(18);xp(19);xp(20);xp(21);
xp(22);xp(23);xp(24);xp(25);xp(26);xp(27);xp(28);xp(29);xp(30);xp(31);xp
(32);xp(33);xp(34);xp(35);xp(36);xp(37);xp(38);xp(39);xp(40);xp(41);xp(4
2);xp(43);xp(44);xp(45);xp(46);xp(47);xp(48);xp(49);xp(50);xp(51);xp(52)
;xp(53);xp(54);xp(55);xp(56);xp(57);xp(58)]; 
 
  end 
end 
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8.7 Trees at best pruning level  
 
 
 
 
Figure: 8.1: Tree of best level as result of model analysis of the EGFR-model 
 
 
 
 
Figure: 8.2: Tree of best level as result of model analysis of the Caspase-model 
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Figure: 8.3: Tree of best level as result of model analysis of the CD95/Fas-model 
 
 
 
 
Figure: 8.4: Tree of best level as result of model analysis of the EARM v1.0-model 
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